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The development of an effective HIV-1 vaccine remains a global priority. Neutralizing 
antibodies (nAbs), which block infection by cell-free virus, are likely to be an important 
response for vaccines to elicit. However, evidence from the RV144 vaccine trial and non-
human primate vaccine studies suggest antibody-dependent cellular cytotoxicity (ADCC) 
responses, which target virus-infected cells, may also be protective. This thesis uses deep 
sequencing, together with immune assays, to characterise HIV-1 Envelope evolution associated 
with both nAb and ADCC responses in early infection, and investigates broadly neutralizing 
and non-neutralizing monoclonal antibody ADCC activity against subtype C viruses. 
Recent advances in deep sequencing approaches, coupled with the primer ID method which 
barcodes each viral genome, enabled us to generate thousands of viral sequences to accurately 
track viral population dynamics in early infection. In all participants investigated, there was a 
significant drop in the relative frequency of wildtype (WT) virus following nAb responses. 
However, in three of the seven participants, when controlling for changes in viral load (VL) 
over time, we observed that the WT load (frequency of the WT residue x total VL) remained 
relatively stable despite an effective nAb response. Instead, there was an outgrowth of the 
escaped virus with a concomitant increase in viral loads. We found that nAbs were inefficient 
at blocking cell-cell transmission of early WT and escape viruses, identifying this as one 
mechanism by which viruses may persist despite the presence of nAbs. These results suggest 
that other antibody effector functions such as ADCC, which target infected cells, may be 
important to elicit in a protective HIV-1 vaccines. 
If ADCC responses are important in controlling viral populations, one would expect to find 
evidence of viral escape from these responses. In all nine participants investigated, we found 
ADCC responses emerged prior to nAb responses, and in three individuals we observed 
sequence changes prior to detectable nAbs. To evaluate if these changes were due to ADCC 
pressure on the virus, we introduced select mutations into infectious molecular clones encoding 
the cognate early/acute envelope (Env-IMCs). In one participant, the mutation introduced 
conferred resistance to both nAb and ADCC responses, while in two participants, mutations 
were identified which resulted in resistance to ADCC but had no effect on neutralization, 
suggesting escape from ADCC. Longitudinal analysis in one of these participants, which 
targeted the CD4-binding site, revealed three distinct escape pathways, of which two conferred 




Finally, we investigated the ADCC activity of eleven anti-HIV-1 monoclonal antibodies 
(mAbs), including seven broadly neutralizing antibodies (bnAbs) and four non-neutralizing 
antibodies (nnAbs), against a panel of nine acute subtype C Env-IMCs. We found bnAbs had 
low to moderate ADCC breadth (11-66%). In contrast, while the two V2 nnAbs we tested were 
narrow and weak, the two nnAbs targeting CD4-induced epitopes (A32 and C11) mediated the 
broadest (78-100%) and most potent (0.06-0.81 µg/mL) ADCC against this panel. In addition, 
a non-linear relationship was found between ADCC activity and strength of mAb binding to 
the infected cell surface (rs = -0.5309, p=0.0001). 
In conclusion, in contrast to studies which evaluated limited number of sequences, utilizing 
deep sequencing approaches, we found that the WT load remained relatively stable following 
early nAb pressure, albeit at lower relative frequency to the escape variant. Evasion of antibody 
responses through cell-cell transmission may contribute to the persistence of WT virus, 
providing further motivation for the importance of antibody effector functions that target 
infected cells in a protective HIV-1 vaccine. For the first time, we provide evidence of ADCC-
mediated immune pressure in early infection, showing that these responses can exert selective 
pressure on HIV-1. However, the limited number of sequence changes relative to those 
observed following nAb pressure suggests that this response does not put as much selective 
pressure on the virus as nAbs. Lastly, the moderate breadth of bnAb ADCC activity provides 
evidence that there are common epitopes on free virions and on the surface of infected cells. 
This indicates bnAbs with potent and broad ADCC should be identified to include in antibody-
based treatment and cure strategies, which aim to eliminate infected cells. Altogether, these 
data suggest that while eliciting nAbs should be the primary goal of HIV-1 vaccine design, 
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1.1  Background 
Remarkable gains have been made in the last decade to manage the Human Immunodeficiency 
Virus-1 (HIV-1) epidemic, the causative agent of Acquired Immunodeficiency Syndrome 
(AIDS). This is largely due to the roll-out of anti-retroviral therapy (ART) which has resulted 
in a 43% decrease in AIDS-related deaths globally since 2003 (1).  ART not only increases 
life-expectancy, but also reduces transmission of HIV-1 from treated individuals to their 
uninfected partners (2). The availability of effective anti-HIV-1 drugs has prompted some to 
doubt the necessity of an effective HIV-1 vaccine, advocating for improved access to ART and 
pursuing HIV-1 cure strategies instead. However, these treatment regimens are not cost-
effective for developing countries, where the majority of the disease burden lies. Furthermore, 
individuals on long-term treatment have other risk factors associated with HIV-1 infection, 
such as peripheral arterial disease, cardiovascular disease and impaired renal function (3–5). In 
addition, despite the decrease in AIDS-related deaths, the number of new infections annually 
has remained relatively constant (there were approximately 1.9 million new infections in 2015), 
largely because treatment has not been implemented early enough and there has been 
insufficient coverage to impact the number of new cases (1). This is particularly true of Eastern 
and Southern Africa, where the greatest burden of the epidemic lies (approximately 70% of 
global HIV-1 infections): in South Africa alone, there were approximately 170 000 new HIV-
1 infections in the 2014-2015 period (6).  
Vaccines have proven to be the most effective method of controlling viral epidemics, reducing 
disease and death in settings where effective vaccines have been implemented (7). 
Consequently, the development and deployment of a safe and protective HIV-1 vaccine 
remains an important goal of HIV-1 research.  However, the development of an effective HIV-
1 vaccine has proven an unusually elusive goal: despite numerous clinical trials utilizing a 
number of different approaches, only one has provided any protection, a modest 31% in the 
RV144 trial (8). One significant challenge in the discovery of an effective vaccine has been a 
lack of understanding of immune correlates of risk and protection. Inadequate animal models 
suggest these correlates can only be identified in costly human efficacy trials (9–11).  
As a result, understanding how people naturally control HIV-1 provides important insights into 
what a protective immune response may look like and how one may go about eliciting such a 
response through vaccination. Indeed, these studies have provided valuable direction in HIV-
1 vaccine research, especially in the last decade. In particular, studies of humoral responses to 
HIV-1 suggest vaccines which elicited these immune response could, theoretically, protect 
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against HIV-1 infection (12). Evidence from vaccination against other viruses supports this 
hypothesis, as antibody responses are the correlate of protection in almost all anti-viral vaccines 
to date (including Smallpox, Hepatitis A and B, Human papillomavirus, Influenza and Polio, 
to name a few) (reviewed in (13)). 
However, these viruses are all much less variable than HIV-1, which has an extraordinary 
global sequence variation (14), making selection of vaccine immunogens a daunting task. 
Further, the astonishingly high rate of virus evolution (reviewed in (15)) allows HIV-1 to 
rapidly evolve. Accordingly, any vaccine candidate must produce immune responses that 
efficiently protect against a range of diverse HIV-1 strains.  
1.2 HIV: Origins, diversity and distribution 
HIV can be divided into two types: HIV-1 and HIV-2, which represent two separate zoonotic 
transmission events (Figure 1.1). While HIV-2 is derived from Simian Immunodeficiency 
Virus (SIV) found in Sooty mangabeys (Cercocebus atys) (16, 17), HIV-1 was transmitted to 
humans through multiple zoonotic events from the SIV reservoir found in the Chimpanzee 
subspecies Pan troglodytes troglodytes and the Gorilla subspecies Gorilla gorilla (18, 19).  
HIV-2 infection is immunologically distinct from HIV-1 (20), much less common 
(geographically restricted to West Africa) and less virulent (21, 22), although it has similar 
clinical presentation to HIV-1 (23). HIV-1 is comprised of four groups, each of which are 
thought to represent a separate zoonotic transmission event: M (main), O (outlier), N (non-M, 
non-O) and P (24–27). Group M, the main cause of the HIV-1 epidemic, consists of nine 
genetically distinct subtypes (A-J) (14), as well as 79 currently identified Circulating 
Recombinant Forms (http://www.hiv.lanl.gov/contents/sequence/HIV/CRFs/CRFs.html) and a 
number of Unique Recombinant Forms, which all produce similar clinical symptoms, but have 
different geographical distributions (Figure 1.2).  
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Figure 1.1. The origin of HIV. Primate lentivirus tree (derived from Pol protein sequences), showing 
the distinct origins of both HIV-1 and HIV-2 (in red). SIV strains have a suffix indicating their species 
of origin (i.e. cpz refers to chimpanzee, mac to macaque etc.) (A). SIVcpz/HIV-1 tree (derived from 
Env protein sequences), showing the distinct origins of HIV-1 groups M, N, and O, and the numerous 
subtypes (A–K) within group M (B). Among the chimpanzee viruses (SIVcpz, in black), Ant was 
isolated from the chimpanzee subspecies Pan troglodytes schweinfurthii and the other strains from Pan 
troglodytes troglodytes. Figure and legend reproduced from (28) with permission provided by Elsevier 
Publishers. 
Figure 1.2 Global distribution of HIV-1 group M subtypes and recombinants. Pie charts 
representing the distribution of HIV-1 group M subtypes and recombinants from 2004 to 2007 in each 
region are superimposed on the regions. The relative surface areas of each pie chart correspond to the 
number of people living with HIV-1 in that region. The colours representing the different HIV-1 
subtypes and recombinants are indicated in the legend on the left-hand side of the figure. The HIV-1 
subtype distributions found around the world and within Central African countries are shown in the 
insets, as indicated. Figure and legend reproduced from (29) with permission provided by Elsevier 
Publishers.  
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Apart from the East, West and Central African epidemics (which contains considerable subtype 
diversity), certain subtypes are dominant in different regions: subtype A is found 
predominantly in Russia and Eastern Europe; Subtype B in Europe, North and South America; 
Subtype C in Sub-Saharan Africa, Ethiopia and India; and CRF01_AE in Southeast Asia 
(Figure 1.2). The burden of the HIV-1 epidemic is geographically biased (as indicated by the 
size of each pie chart in Figure 1.2): Eastern and Southern Africa contain ~ 70% of all HIV-1 
infections (~ 19 million out of 35 million), Western and Central Africa contain ~ 6.5 million 
infections, while Asia and South-East Asia contain ~ 5.1 million infections (14). The 
substantial genetic diversity (and consequently, antigenic diversity) represents considerable 
challenges to attempts to design an effective global vaccine.  
1.3  The HIV-1 genome 
HIV-1 is a single-stranded, positive-sense RNA, enveloped virus, classified in the genus 
Lentivirus of the family Retroviridae, and predominantly replicates in CD4+ T cells. The viral 
genome consists of nine genes (gag, pol, env, tat, rev, nef, vif, vpr and vpu) (Figure 1.3, A) 
which encode for 19 proteins (reviewed in (30)). Gag, pol and env encode for the structural 
proteins of the virion: Gag encodes for the Gag polyprotein which is cleaved into proteins 
which shape the basic interior infrastructure of the virus (matrix, capsid, nucleocapsid, spacer 
peptides 1 and 2 and p6 proteins), pol encodes for the Polymerase polyprotein which is cleaved 
into the virus enzymes (Reverse Transcriptase, Integrase, Protease and RNase-H) which 
provide the basic mechanism by which the virus replicates, and env encodes for the Envelope 
(Env) proteins which coat the surface of the virion and facilitate viral attachment (gp120) and 
fusion (gp41) with target cells. The HIV-1 genome also encodes two essential regulatory 
proteins (Tat and Rev) and four accessory proteins (Nef, Vpr, Vif and Vpu). These components, 
together with the structural proteins and two single-stranded, positive-sense RNA copies, 
usually makeup the HIV-1 viral particle (31) (Figure 1.3, B). 
The error prone nature of the HIV-1 Reverse Transcriptase enzyme is largely responsible for 
the extensive genetic variation observed at both an individual and population level. The enzyme 
does not contain a proof-reading mechanism, resulting in a high rate of mutation (~ 0.2 errors 
per genome replicated) and extensive recombination during reverse transcription (32). This, 
together with remarkable replication dynamics (a single virion requires ~ 42 hours to complete 
the replication cycle (33), and 1010 - 1012 new virions are produced each day (34)) and strong 
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pressure from immune responses at an individual level, results in the abnormally high rate of 
evolutionary change. The corresponding genetic variation is especially evident in the HIV-1 
env (particularly in the hypervariable regions of the gp120 (35)), which has an evolution rate 
of approximately 0.004 substitutions per site per year at the population level (36). 
 
Figure 1.3 Genome and structure of HIV-1. Genomic organization of HIV-1 showing the three 
structural genes (gag, pol and env) and six regulatory genes (tat, rev, nef, vpr, vif and vpu), which are 
spread over three reading frames (A). A representation of the structure of the HIV-1 virion (B). Figure 
and legend reproduced from (37) under a creative commons licence. 
1.3.2 The gp120 Envelope glycoprotein 
The env gene encodes for the gp160 Env glycoprotein, which is located on the outer surface of 
the virion and is the viral component exposed to the humoral immune response. Env consists 
of two protein subunits: gp120 (an external protein) and gp41 (a transmembrane protein) (38) 
(Figure 1.4). The gp120 external protein of the Env trimer is made of up five variable regions 
(V1-V5) and five constant regions (C1-C5) (39, 40). Within the gp120, nine cysteine-cysteine 
A 
B
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disulphide bonds form, four of which traditionally define the stems of the variable loops V1, 
V2, V3 and V4 (41).  
Figure 1.4 Linear schematic of the HIV-1 Envelope. The precursor gp160 is cleaved into two 
monomers, gp120 (blue) and gp41 (green). The gp120 subunit consists of five constant domains (C1-
C5, shown in light blue) and five variable domains (V1-V5, shown in dark blue). The gp41 subunit 
(green) consists of the fusion peptide (FP), heptad-repeats (HR1 and HR2), a disulphide loop (DSL), 
the membrane-proximal external region (MPER), the transmembrane domain (TD) and the cytoplasmic 
tail (CT). The positions of common N-linked glycosylation sites are shown in black. Figure and legend 
adapted from (42) with permission provided by The American Association for the Advancement of 
Science.  
HIV-1 binds to the CD4-receptor on the surface of target cells, which results in initiation of the 
cell entry process. The CD4-binding site (CD4bs) is a conserved, pocket-like structure which 
has been mapped to a complex, discontinuous surface of the gp120 with numerous contact 
residues residing within several domains (including the C2, C3, C5 and the stem of the V5) 
which fold into proximity in the Env tertiary structure (43). The gp120 undergoes a substantial 
refolding upon binding to the CD4 receptor (known as CD4-induced conformational changes), 
which subsequently allow the formation of the co-receptor binding surface (44–47).  
Following CD4 binding, HIV-1 gp120 binds to host co-receptors CCR5 or CXCR4 to enable 
efficient entry into target cells. The co-receptor binding site is made up of multiple residues 
found around the bridging sheet, V3 and C4 (48–50). Reorganisation of trimeric gp120 
following CD4 binding re-orientates the V3 loops toward the host membrane, allowing the top 
of the V3 loop to bind the second extracellular loop of the CCR5, positioning the Env for fusion 
with the target cell membrane (51). 
The V3 loop is the main determinant of co-receptor tropism, facilitating binding to either the 
CCR5 or CXCR4 co-receptors. Transmitted viruses utilize the CCR5 receptor, with almost no 
exception. However, some viruses undergo a switch, enabling them to use the CXCR4 receptor 
during the course of infection (52). The switch between CCR5 and CXCR4 co-receptor tropism 
has been linked with mutations in the V3, which increase the net positive charge of the V3 
allowing interaction with the negatively charged surface of CXCR4, and has been associated 
with faster disease progression (53, 54). 
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With the exception of the V3 loop, which shows relatively low length variation, the variable 
loops range considerably in length and largely assist in immune evasion and escape (55). In 
particular, the V1V2 domain varies substantially in length and glycosylation profile (56–59). 
This large loop, together with its extensive glycosylation, has been implicated in the occlusion 
of the CD4bs (60–62) and the co-receptor binding site. 
The Env protein is heavily glycosylated (Figure 1.4, shown in black), with up to half of the 
Env’s molecular weight attributed to glycans (63): a gp120 molecule has 20 – 35 N-linked 
glycosylation sites and a gp41 molecule has 3 – 5 N-linked glycosylation sites. The glycans 
incorporated onto the Env are attached by host cellular machinery in the golgi, allowing them 
to act as a non-immunogenic barrier to the underlying peptide structure, and consequently 
facilitate escape from the immune system (64). In addition to this, glycosylation has been 
linked with virus infectivity and virus-induced fusion (65),  correct folding of the Env (66), and 
processing and transport in the Golgi apparatus (67). 
1.3.3 The gp41 Envelope glycoprotein 
While the gp120 glycoprotein facilitates binding to target cells, the gp41 glycoprotein mediates 
fusion of the virion and target cell by allowing the virus membrane to come into close proximity 
with the target cell membrane. The protein is organized into three domains: an external domain, 
a transmembrane domain and a cytoplasmic tail (reviewed in (55)).  
The external domain incorporates the regions prominent in the fusion process: an N-terminal 
hydrophobic region known as the fusion peptide (FP) (68, 69), two hydrophobic regions which 
form α-helical coiled-coil structures referred to as heptad-repeat regions (HR1 and HR2), 
which are linked by a disulphide link (DSL) (70–74), and a Tryptophan-rich region referred to 
as the membrane-proximal external region (MPER) (75, 76) (Figure 1.4).  
The FP is hidden deep within the trimer, where the gp120 and gp41 interact, but becomes 
exposed following binding of the gp120 to the CD4 receptor, allowing penetration of the FP 
into the target cell membrane and subsequent membrane destabilization (Figure 1.5). Three 
HR1 motifs form a core bundle in parallel and fold over a hydrophobic groove antiparallel to 
three HR2 domains within each trimer (Figure 1.5), forming a stable six-helix bundle which 
brings the viral and cell membranes in close enough proximity for fusion to occur (71). The 
MPER makes up the remaining 24 residues of the gp41 extracellular domain. It is a highly 
conserved region and is essential for both fusion and infection (75–78). 
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Figure 1.5 HIV-1 fusion. Binding of the gp120 subunit (green) of the trimeric Env glycoprotein to the 
CD4 receptor and the chemokine co-receptor (CXCR4 or CCR5) triggers a conformational change in 
the unmasked subunit gp41 (grey and violet), where two regions, the N-terminal HR1 (grey), and the 
C-terminal HR2 (violet) become separated in the so-called “hairpin intermediate,” which bridges the 
viral and cell membranes. Collapse of the hairpin intermediate into a 6-helix bundle drives viral–cell 
membrane fusion. Figure and legend adapted from (79) with permission provided by The National 
Academy of Science. 
The remaining two regions of the gp41 are the transmembrane (TM) domain and the 
cytoplasmic tail (CT). The TM domain is a hydrophobic region which is likely to span the viral 
membrane three times (80), although a structure has not yet been resolved, and is involved in 
the formation of fusion-competent Env protein (81). To conclude, the gp41 CT is unusually 
long for a TM protein (~ 150 residues). A number of studies have implicated it in a diverse 
range of functions, including Env incorporation into the virus (82, 83), interaction with viral 
matrix proteins (83–86) and targeting to vesicles (87–89).  
1.3.4 HIV-1 Envelope features and states 
The Env spikes on the surface of virions are comprised of three gp120 and three gp41 subunit 
glycoproteins, which come together to form the ‘closed’ heterotrimeric Env protein (Figure 
1.6).  The Env structure was recently resolved in crystallography and cryo-electromicroscopy 
studies, to a resolution of 4.7 Å and 5.8 Å respectively (42, 90). The successful crystallization 
of the Env trimer was a boost for the HIV-1 vaccine field, allowing accurate predictions of 
antibody epitopes and angles of binding. This opened opportunities for rational vaccine design 
of Env-based immunogens.   
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Figure 1.6 Schematic of the HIV-1 Envelope trimer. Three gp120 subunits (blue) sit on three gp41 
subunits (red) (side view on the left, top view on the right). The variable loops make up the outer domain 
of the trimer. Figure produced using the Envelope trimer crystal structure (PDB ID: 4NCO) (91) and 
PyMOL 1.8 (92).  
Env is found in several states on the viral membrane, making immunogen selection difficult. 
The highly ordered, unliganded conformation of the Env trimer is referred to as the ‘closed’ 
conformation (93). Binding of CD4 to the CD4bs induces significant conformational changes, 
such that the trimer adopts an ‘open’ configuration (where the V1V2 and V3 loops are 
‘unattached’ and no longer shield conserved epitopes) (94). However, the trimer does spend 
some time in the ‘open’ state independent of CD4 binding. The CD4-independent equilibrium 
between the ‘open’ and ‘closed’ states varies from Env to Env: most Envs predominantly 
remain in the ‘closed’ state, while some Envs switch between the ‘open’ and ‘closed’ states 
regularly (94) (Figure 1.7). 
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Figure 1.7 HIV-1 Envelope configurations. Env trimers exist predominantly in the closed form in 
which the interactions between V1/V2 from each protomer are intact and V3 is occluded. Transient 
sampling of open conformations disrupts the inter-protomer interactions at the trimer apex. The 
trimers on higher tier (more neutralization resistant) viruses are less likely to sample open 
conformations, thereby protecting conserved epitopes from neutralizing antibodies. Tier 1 primary 
and cell line-adapted isolates sample the open conformation more often or for longer periods, which 
renders these viruses more vulnerable to neutralization. Figure and legend adapted from (94) with 
permission provided by Nature Publishing Group.  
These conformations have a profound effect on the ability of antibodies to neutralize the virus. 
Two studies have ranked several hundred Envs into tiers based on their susceptibility to 
neutralization, with tier 1 Envs being highly susceptible to neutralization and tier 3 Envs highly 
resistant to neutralization (95, 96). Tiering of the Envs has been associated with the state of 
equilibrium between ‘open’ and ‘closed’ Env configurations: tier 1 Envs predominantly remain 
in the ‘open’ state, while the converse is true for tier 3 Envs (94). Tier 1 viruses are not normally 
detected in natural infection, necessitating immune responses to the closed trimer as a 
requirement for an effective vaccine. 
In addition to the complication this relative equilibrium between structural states signifies for 
vaccine design, several other HIV-1 Env features make the discovery of a successful vaccine a 
daunting task. These include the considerable antigenic variability, heavy glycosylation and 
conformational masking of receptor binding sites by variable loops (97) (previously described).  
Furthermore, several other Env features are important in HIV-1 vaccine design including 
transient exposure of epitopes (such as epitopes on the MPER) (98), the presence of non-
functional Env on the viral membrane surface (99, 100), and the low density of Env surface 
expression, making antibody cross-linking difficult (101, 102) (Figure 1.8). 
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Figure 1.8 Envelope-dependent defence mechanisms of HIV-1. As well as from the Env antigenic 
variability, several architectural and structural features of the HIV-1 spike limit or block the access of 
immune effectors: (i) Many host-derived glycans cover the surface of the spike to form a ‘glycan 
armour’ protecting the virus; (ii) some epitopes are only transiently exposed, such as the ‘pre-fusion 
state’ form of gp41 and the co-receptor binding site that opens following a conformational change 
induced by the interaction of gp120 with a CD4 molecule (CD4i); (iii) conformational masking of the 
CD4bs prevents access; (iv) steric occlusion of immunoglobulins due to their large size; (v) epitopes on 
non-functional spikes (non-cleaved Env precursors, gp120 monomers, and gp41 trunks), which are not 
expressed by mature functional spikes, are a highly immunogenic decoy; and (vi) the small number of 
gp160 glycoproteins (∼ 15 per virion), which are randomly distributed at the HIV-1 surface, likely 
impair the ability of the antibody to bridge two Env (bivalent antibody binding), therefore reducing 
avidity effects. Figure and legend reproduced from (103) with permission provided by Elsevier 
Publishers. 
1.4  HIV-1 transmission 
HIV-1 is detected in blood, as well as other bodily fluids, from infected individuals. 
Transmission results from exposure of an uninfected individual to virus-containing fluids from 
an infected individual. In Africa, the vast majority of transmission events are the result of 
heterosexual sex with an infected partner. Despite high viral loads in bodily fluids, 
approximately 80% of heterosexual infections are established from a single HIV-1 variant 
(termed the transmitted/founder (T/F) virus) (104, 105), suggesting the transmission event 
contains one or more selective genetic bottlenecks (for a comprehensive review, see (106)).   
One potential bottleneck is the compartmentalization of viral populations in the genital tract, 
which has been shown to include both clonally amplified and diverse transient lineages (107–
109). This clonal amplification, which has been identified in both male and female genital 
secretions, is consistent with a model by which inflammation drives HIV-1 replication from a 
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small collection of singly infected T cells (106). While the dominant variant in the genital 
compartment may have a greater chance of transmission due to their higher frequency, in one 
transmission pair study (with sampling between 2 and 12 weeks after the transmission event) 
it was found that T/F viruses were a minority variant in the genital tract of the donors (108). 
However, due to the timing of sampling and the transient nature of genital tract clonally-derived 
viruses, it is difficult to draw conclusions about the frequency of the transmitted viruses in the 
donors from this study.  
The most stringent transmission bottleneck is thought to be in the genital tract of the recipient, 
where typically a single genotype initiates systemic infection (Figure 1.9). Many studies have 
shown that this bottleneck results in several characteristics generally found in T/F viruses. 
Firstly, T/F viruses are nearly always CCR5-dependent and require high surface levels of CD4 
on the target cells for entry (105, 110). Secondly, there is an apparent differential in variable 
loop lengths, and consequently levels of glycosylation, between T/F and chronic viruses: T/F 
subtype A, C and D viruses contain fewer N-linked glycosylation sites (57, 110, 111), while 
this pattern is less obvious in subtype B viruses (57, 112, 113).  
The Env density on the surface of the virion may also favour transmission of certain variants: 
one study, which used infectious molecular clones (IMCs), found the density of Env on the 
surface of the viral membrane of T/F viruses was double that found on IMCs of chronically 
derived viruses (114). This may increase the probability that a virus attaches to and infects a 
target cell in the genital mucosa (106). There is also evidence to suggest T/F viruses display 
enhanced binding to Dendritic cells (114). This would then allow efficient transport of T/F 
viruses from the epithelial surface of the genital tract, where there is a relatively high density 
of Dendritic cells, to the stroma or lymphoid tissue, where the virus can be presented to, and 
infect, CD4+ T cells (115, 116).  
However, the most convincing evidence of a transmission bottleneck has been recently shown 
by Iyer et al., who studied the properties of plasma and genital secretion-derived viruses from 
eight donor and recipient pairs (117). Here, they found that recipient viruses were 
approximately three-fold more infectious than donor viruses, replicated to slightly higher titers 
and were released from infected cells 4.2 times more efficiently. In addition, recipient viruses 
were significantly more resistant to type I interferons (IFN): transmitted viruses were 7.8-fold 
more resistant to IFN-α2 and 39-fold more resistant to IFN-β. These results indicate that the 
mucosal bottleneck selects for viruses which can replicate efficiently in the presence of a potent 
innate immune response. 
Chapter 1 - Introduction and literature review 
14 
Figure 1.9 The transmitted/founder virus is shaped by multiple genetic bottlenecks. Chronically infected 
individuals have extremely diverse HIV-1 populations in their blood. Some viruses from the blood seed 
the genital tract of the donor, where the resulting viral population is less diverse than in the blood and 
is often dominated by a few clonally amplified variants. It is unknown whether replication in the genital 
tract selects for specific phenotypes. Viruses sampled from the donor genital tract are present in the 
transmission fluids (cervicovaginal mucus, semen or rectal secretions). The vast majority of viruses 
within the transmission fluid do not penetrate the genital or rectal mucosa of the recipient. Damage due 
to sexually transmitted infections or intercourse can increase the ability of viruses to penetrate the 
mucosa. Most of the viruses that can infect the recipient genital tract have a low reproductive rate 
(R0 <1) owing to low densities of target cells, low viral fitness or susceptibility to host defences (such 
as phagocytosis or production of interferons) and will not contribute to the systemic infection. 
Typically, when a systemic infection is established after sexual exposure to HIV-1, the initial viral 
population in the recipient's blood will be genetically homogeneous because it was established from a 
single viral genotype (the transmitted/founder virus) that could replicate in the recipient genital tract. 
On progression to the chronic stages of infection, infected individuals display extremely diverse HIV-
1 populations in their blood. Figure and legend adapted from (106) with permission provided by Nature 
Publishing Group. 
1.5 Adaptive immune responses to HIV-1 
1.5.1 Cytotoxic T-lymphocyte immune responses 
While the RV144 trial provided some understanding of immune correlates associated with 
transmission risk, additional studies are still needed. Studies on the immune response to the 
virus in natural infection are being conducted in the hopes that this will provide valuable insight 
into how to design a protective vaccine (118, 119). One of the first, and most important, 
adaptive immune responses to HIV-1 infection is the cytotoxic T lymphocyte (CTL) response. 
HIV-1-specific CTLs emerge two to three weeks after infection and play an important role in 
suppressing viral replication during both acute and chronic infection (120–122). In this 
adaptive process, viral peptides are processed and presented on Major Histocompatibility 
Complex (MHC) class I molecules (also known as Human Leukocyte Antigen (HLA) in 
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humans) on the membrane of the infected cells. T cell receptors (TCRs) expressed on the 
surface of CTLs then bind specifically to the MHC molecule with the viral peptide, which 
induces the release of perforins and proteases from the CTLs which lyse the infected cells 
(123). 
HIV-1 has evolved several mechanisms to avoid recognition by CTLs. The first of these is non-
mutational whereby the accessory protein Nef mediates a mechanism which leads to 
downregulation of MHC class I molecules on the surface HIV-1-infected cells, resulting in a 
lack of recognition by CTLs (124, 125). A second mechanism of escape involves the mutation 
of amino acids in viral epitopes which bind to MHC class I molecules or TCRs, resulting in 
loss of recognition by CTLs (126–129). 
The effectiveness of the CTL response is complicated by the genetic diversity present among 
individuals from different populations. HLAs are grouped into subfamilies of closely related 
variants: HLA corresponding to MHC class I has three major genes (HLA-A, B and C) and 
three minor genes (HLA-E, F and G) (130). A large number of studies have shown that 
variation in HLA types is associated with disease progression, establishing that an individual’s 
HLA profile determines their response to HIV-1 epitopes (131–134). Consequently, some HLA 
alleles are more protective, resulting in slower disease progression (135–138), such as HLA 
B*27:05, HLA B*57:01, HLA B*58, while other alleles, such as HLA B*35, HLA B*53 and 
HLA B*5802, are associated with rapid progression (139, 140).  
1.5.2 Antibody-mediated immune responses 
In addition to CTL immune responses, the other major adaptive immune arm against HIV-1 is 
the humoral response. The humoral responses have been correlated with protection in other 
anti-viral vaccines (141–144). This response is mediated through B cells and first becomes 
detectable in the form of antibody complexes, 8 to 20 days after virus is detected in the plasma 
(145, 146). Free antibodies, directed toward the HIV-1 gp41, are detectable in the plasma from 
approximately 14 days after detectable viremia. and a further 14 days are required before anti-
HIV-1 gp120 antibodies (Figure 1.10 A and B) are detected in plasma (145, 146).  
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Figure 1.10 The antibody response to HIV-1. These responses occur in stages, shown here in a 
clockwise direction starting at the top. The initial antibody response to HIV-1 is non-neutralizing and 
directed at gp41 (A). Soon thereafter non-neutralizing antibodies arise directed against gp120 (B). After 
a delay of weeks to months, autologous neutralizing antibodies arise that apply selection pressure on 
the virus (C). Viral mutation results in neutralization escape by HIV-1, represented here by a change in 
the shape of gp120 (D). In some patients, antibodies that can neutralize a wide range of HIV-1 isolates 
arise, represented here by a variety of shapes of gp120 (E). Figure and legend reproduced from (145) 
with permission from the Journal of Infectious Diseases. 
These early antibodies are non-neutralizing and are elicited in all infected individuals against 
many different proteins (although Env elicits the strongest responses) (147–150). While these 
antibodies are not able to prevent cell entry, they function by binding to Env on the surface of 
viral particles or infected cells and elicit antibody effector functions, such as antibody-mediated 
virus opsonisation, resulting in complement cascade or phagocytosis (151–153) (Figure 1.11 
B, C), antibody-dependent cellular cytotoxicity (ADCC) (Figure 1.11 D), antibody-dependent 
cell-mediated virus inhibition (ADCVI) or mucosal trapping (154, 155).  
Chapter 1 - Introduction and literature review 
17 
Figure 1.11 Antibody functions against HIV-1. Free virus neutralization by antibodies (A), free virus 
and infected cell complement-mediated lysis facilitated by antibodies (B), Antibody-mediated virus 
particle opsonisation and phagocytosis via Fc or complement receptors (C), antibody-dependent cellular 
cytotoxicity (ADCC) against infected cells (D). Neutralizing antibodies (red), non-neutralizing 
antibodies (blue), Fc receptor (violet), complement components (light blue), complement receptors 
(blue). Figure and legend reproduced from (156) with permission provided by John Wiley and Sons 
Publishers.   
1.5.2.1 Neutralizing antibody responses 
Neutralizing antibodies (nAbs) (Figure 1.10 C) prevent HIV-1 entry into target cells by binding 
to Env through the antigen binding fragment (Fab), coating viral particles and inhibiting 
binding of the virus to host cell receptors, CD4 and CCR5/CXCR4, as well as preventing fusion 
to the target cell membrane (Figure 1.11 A) (157).  
Strain-specific nAb responses, which only target the virus which elicited them, usually appear 
from one to three months post-infection (146, 158–160). These responses develop after acute 
infection and are thought to be ineffective at controlling infection (158, 159, 161). This is likely 
because they often target a single specificity, predominantly in the Env variable regions (162–
164). This allows the virus to rapidly escape (Figure 1.10 D) through several pathways; 
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including changes in N-linked glycosylation, point mutations and insertion/deletions (indels) 
(159, 164). Point mutations allow escape from nAbs by resulting in charge/shape changes in 
the epitope of the antibody (161), while N-linked glycosylation and indels (particularly in the 
variable loops) result in shielding of the nAb epitope (56, 165). 
1.5.2.1.1 Broadly neutralizing anti-HIV-1 antibodies 
A special subset of nAbs, broadly neutralizing antibodies (bnAbs), are capable of neutralizing 
many different virus strains, and as a result, are a highly desired outcome of an HIV-1 vaccine 
(157). However, most bnAbs only develop 2-4 years post infection (118, 166–168), and only 
in approximately 10-25% of individuals (118, 162, 169–171). Five major bnAb specificities 
have been discovered to date and include those targeting the CD4bs, the V1V2 loop, the V3 
loop glycans, the MPER and the gp120/gp41 bridge (12) (Figure 1.12). BnAbs often have 
unusual features such as extensive somatic hypermutation, suggesting that affinity maturation 
is essential for the development of neutralization breadth (172). Further, some have unusually 
long complementary determining region 3’s (CDR3s) (173, 174), presumably to enable the 
antibody to penetrate the glycan shield.  
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Figure 1.12 Sites of vulnerability on HIV-1 Envelope glycoprotein. The HIV-1 Env crystal structure 
(42) (PDB ID: 4NCO) was modelled onto the cryoelectron microscopy reconstruction of an unliganded
membrane-bound HIV-1 Env trimer (175) (EMDB: 5019 and 5021). Env model that was used was fully
glycosylated using predicted glycoforms (except for gp41, gp120 V2 and V4 loops, whose glycans were
not modeled because of the disorder of those protein regions in the crystal structure or uncertainty in
registry assignment). The figure was generated using UCSF Chimera (176). N160-dependent V1/V2
loops (orange), N332-dependent V3 loop (purple), CD4 binding-site (pink) and glycans-dependent
gp120/gp41 bridging region epitopes (blue and red) are highlighted as defined by PG9 (91, 177),
PGT128 (178), VRC01 (172), 8ANC195 (179) and PGT151 (180) binding. The MPER of gp41, for
which only limited structural information is available in the context of the HIV-1 Env trimer, is also a
site of vulnerability and is highlighted in yellow. BnAbs specifically mapped to each site of
vulnerability are indicated in boxes. Figure and legend reproduced from (103) with permission provided
by Elsevier Publishers.
1.5.2.2 Fc-mediated antibody effector functions 
Antibodies mediate effector functions through the Fc (Fragment, crystallisable) region of the 
antibody. The Fc region binds to Fc receptors (FcRs) on effector cells such as Natural Killer 
cells (NKCs), Monocytes, Dendritic cells and Neutrophils (181) as well as other cells, and are 
essential for a comprehensive immune response against many pathogens (182–188). NKCs are 
able to mediate the killing of infected cells which display antibody-bound antigen, or mediate 
virus inhibition, after binding to the antibody-antigen complexes (189–191). NKC activity is 
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dramatically elevated during acute infection prior to the CD8+ T cell response and is the 
dominant cytolytic effector population during acute HIV-1 infection (192–194).  
Within the family of FcRs, the FcγRs (primarily FcγRI, FcγRIIa and FcγRIIIa) are of particular 
interest. These receptors bind IgG antibodies and initiate activation of effector cells in the 
presence of HIV-1 (195–197). FcγRI receptors are upregulated in monocytes and mature 
dendritic cells in acute HIV-1 infection (198), with decreased levels of these receptors observed 
over the course of infection (198), possibly due to Nef which is thought to downregulate these 
receptors.  
FcγRs on effector cells, such as NKCs, can also bind to the Fc domain of antibodies bound to 
the surface of infected cells, and mediate ADCVI. This often includes secretion of antiviral 
factors, such as IFN-γ, as well as cytokines and chemokines by NKCs (199, 200, 328). In 
addition, FcRs on effector cells bound to antibody-antigen complexes on the surface of infected 
cells via the antibody Fc, may activate effector cells and, subsequently, result in ADCC. This 
involves the release of perforin, granzyme and Fas ligand by effector cells and, consequently, 
the death of the infected cell (200).  
1.6 Antibody-dependent cellular cytotoxicity 
1.6.1 ADCC and HIV-1 infection 
ADCC and ADCVI responses can effectively harness the innate immune system early in acute 
HIV-1 infection. This may explain several recent studies which suggest ADCC plays a role in 
protection from HIV-1 acquisition and disease progression (8, 186). Among these, some studies 
have revealed that bnAbs partially protect via effector function, facilitating these functions via 
the Fc region. The role of antibody effector functions in protection against SHIV (an HIV-
1/SIV chimera) has been implied through an Fc domain-deficient bnAb (b12) study, which 
showed moderately decreased protection against SHIV compared to the complete b12 antibody 
(201). This decreased protection may be due to less efficient neutralization of free virions, but 
is more likely due to decreased effector functions (202). A number of other studies have showed 
that removing FcγR-mediated activity results in decreased protective effect of bnAbs, 
supporting this conclusion (203, 204). One of these studies, by Forthal el al., showed that 
interactions between NKCs and the Fc domain results in enhanced antibody neutralization 
(204), suggesting nAbs function via the Fc domain, in addition to neutralization.  
Fc function also plays a role in nnAb activity, which results in effector functions, such as 
ADCC activity, observed as early as 3 weeks post infection (205). Studies of this activity, 
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through in vitro and in vivo experiments, suggest that ADCC and ADCVI may play an 
important role in HIV-1 control (183, 206–214).  
Further evidence of the importance of ADCC responses is documented in studies conducted on 
samples from naturally infected humans. These include mother-to-child transmission studies 
by Broliden et al. and Overbaugh et al., where ADCC responses were linked with enhanced 
protection. These studies provide evidence that ADCC-mediating nnAbs transmitted via breast 
milk from the mother to infant enhanced protection of the infant from HIV-1 acquisition or, if 
acquisition occurred, slowed progression to disease (215, 216). In one of these studies, weak 
nAb activity was detected in 4 of the 19 women and was not associated with protection. ADCC 
responses, however, were detected in all of the women and was inversely associated with infant 
infection risk (216), suggesting ADCC has a role in protection against HIV-1 transmission.  
Numerous other studies have observed that ADCC responses were enriched in HIV-1 non-
progressors (151, 183, 186, 209, 217–220). In contrast, a lack of an ADCC/ADCVI response 
may lead to reduced control of HIV-1 infection (183, 208, 221). Interestingly, a study 
conducted by Delfraissy et al. noted potent ADCC activity was detected in all elite controllers 
in their cohort (10/10), yet was only found in 40% of viremic individuals (4/10) (186), 
suggesting ADCC may also have an important role in HIV-1 control. 
Lastly, these findings are corroborated in a number of non-human primate (NHP) studies which 
showed ADCC-inducing antibodies were enriched in plasma of subjects with non-progressive 
disease in SIV-infected NHPs (205, 206, 212, 213). Another NHP study showed SIV viral load 
decline coincident with ADCVI activity. Interestingly, this containment was against 
phylogenetically divergent and neutralization-resistant viruses (189). The ability to contain 
divergent HIV-1 strains suggests that the antibodies which elicited this function targeted 
conserved regions of SIV and, consequently, warrant further study. In NHP vaccine studies 
using replicating Ad5hr-SIV prime, with an Env boost, strong systemic and mucosal antibodies 
which mediated ADCC activity were correlated with better control of acute viremia (206, 221). 
1.6.2 ADCC in immunization studies 
The RV144 Thai trial, which showed 31.2% vaccine efficacy, is the only protection achieved 
thus far by an HIV-1 vaccine (149). However, this efficacy did not correlate with nAb or 
cellular responses as predicted, but rather with nnAb responses to the V1V2 and V3 regions 
(8). Further, V3-specific ADCC antibodies were implicated, but not correlated, with protection 
from infection (222). 
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Evidence of the protective response offered by nnAbs is supported by several important NHP 
studies. A passive NHP immunization study by Moore et al. found that immunization of 
macaques with F240 nnAbs (which target an immunodominant epitope of gp41) and then 
vaginal challenge with SHIV protected two out of five macaques from infection, with F240 
decreasing the viral load of a further two, compared to the control macaques (NS1, anti-
Dengue), which all became infected (223). This finding importantly showed neutralizing 
activity is not necessary for protection.  However, the underlying mechanism of this protection 
is unknown and this study suggests deeper analysis of nnAb effector mechanisms in HIV-1 
immunity is required. 
Vaccine studies in NHPs have shown that at least some of the protection provided by nnAbs is 
through ADCC and ADCVI mechanisms. Barouch et al. vaccinated NHPs with 
adenovirus/poxvirus and adenovirus/adenovirus vaccines expressing SIVsmE543 Gag, Pol and 
Env antigens which resulted in > 80% reduction in per-exposure probability of infection (224). 
This vaccine provided protection against the acquisition of the highly pathogenic, heterologous 
and neutralization-resistant SIVmac251 virus and correlated with both peripheral and mucosal 
Env-specific IgG. Further, delayed disease progression largely correlated with Env-binding 
antibodies and ADCC responses (224).  
A similar NHP vaccine study, using SIV recombinants, elicited nnAbs with ADCC activity 
against SIV-infected cells. These recombinants stimulated production of nnAbs with strong 
ADCVI and ADCC activity (214). Moreover, production of nnAbs led to transcytosis 
inhibition and reduced chronic viremia (214), providing in vivo evidence that this mechanism 
of protection against acquisition and disease production is important.  
Several other studies in NHPs showed vaccine candidates elicited ADCC antibody titers that 
did not protect from infection but did correlate with control of viral replication after mucosal 
challenge (201, 224), or with reduced acute viremia in vivo, after mucosal challenge (212). 
Lastly, macaques vaccinated with tat/env replication-competent adenovirus elicited nnAb 
activities which had a significant impact on challenge outcome when challenged with SHIV. 
Acute phase protection correlated with Tat- and Env-binding antibodies, but anti-Env 
neutralization activity was not detected (225). Furthermore, ADCVI correlated significantly 
with better acute phase protection (213). Research on the epitopes which elicited these nnAbs 
would be beneficial: while it is known the nnAbs elicited are specifically anti-Env, knowledge 
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of the specific epitopes targeted could provide helpful insight into how strong ADCVI activity 
is elicited. 
1.6.3 ADCC epitopes and escape 
ADCC antibodies are generally thought to target HIV-1 proteins presented on the surface of 
infected cells. For this reason, the majority of epitope discovered to date are either in the gp120 
(203, 226, 227) or gp41 (148). These epitopes have been comprehensively reviewed by Pollara 
et al. (228) and are summarised in Table 1.1 (reproduced from (228)).  
In gp120, several epitopes have been mapped, including the CD4bs (203, 229, 230), the V2 
region (231) and the V3 region (191, 203). Further to this, a number of studies have shown 
ADCC epitopes which are only present following the binding of CD4 to the gp120 (CD4 
induced (CD4i) epitopes) (191, 229), suggesting that gp120 on the surface of cells may have 
another structure which exposes these epitopes or that ADCC also takes place as target cells 
are in the process of being infected. Studies investigating the gp41 region have described 
epitopes in cluster I (an immunodominant region of the gp41) (148), HR2 (148) and the MPER 
(148, 154). 
Of particular interest is a study conducted by Ferrari et al. on the monoclonal antibody A32, 
which binds a conformational epitope including the C1 region (229). This antibody could 
potently induce ADCC (but not neutralize) in the presence of soluble CD4, but lacked 
significant neutralizing or ADCC activity in the absence of CD4, highlighting the difference in 
epitopes between neutralizing and ADCC-eliciting antibodies. 
An important indicator of the importance of ADCC responses would be their ability to force 
immune escape. However, only a few studies thus far have illustrated ADCC-specific immune 
escape (reviewed in (232)). One such study by Chung et al. showed escape in the Env in chronic 
infection using peptides with known ADCC epitopes, and measuring NK cell activation (233). 
However, as only linear epitopes could be mapped using peptides, this method of screening is 
expected to considerably underestimate the epitopes and escape from ADCC antibodies. In 
order to map conformational ADCC epitopes and their escape, whole Env or infectious 
molecular clones need to be constructed (232).  
Additionally, the complexity of humoral immune responses to the HIV-1 Env as infection 
progresses makes unravelling escape from ADCC difficult: as infection continues and nAb 
responses become detectable, escape from nAb responses, which likely overlap (at least to 
some degree) with ADCC responses, may confound results (228). However, this can be 
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overcome by demonstrating escape from ADCC responses in early HIV-1 infection, when 
ADCC responses are detectable but autologous nAbs have not yet developed.  
Table 1.1 Defined Regions of the HIV-1 Envelope Targeted by Human anti-HIV-1 mAbs 















gp41 Cluster I 246-D Linear Non-neutralizing (234) 
4B3 Linear Non-neutralizing (234) 
98-43 Linear Non-neutralizing (148) 
50-69 Discontinuous Non-neutralizing (148) 
Cluster 
II (HR2) 
98-6 Discontinuous Non-neutralizing (148) 
126-50 Discontinuous Non-neutralizing (148) 
Not 
defined 
31710B Not defined (203) 
MPER 120-16 Linear Non-neutralizing (148) 
2F5 Linear Neutralizing (154, 234) 
4E10 Linear Neutralizing (234) 









17B Discontinuous Neutralizing (229) 




i5, L9-i2, N12-i3, 
N26-i1 
Discontinuous Non-neutralizing (235) 
CD4i 
Cluster B 






































Discontinuous 2/6 Neutralizing (235) 


















2G12 Discontinuous Neutralizing (236) 
C5 670-D Discontinuous Neutralizing 
750-D Not defined Non-neutralizing 




15e Discontinuous Neutralizing 
F105 Discontinuous Neutralizing 
448-D Discontinuous Neutralizing 
1125H, 5145A Discontinuous Neutralizing (203) 
b12 Discontinuous Neutralizing (230) 
VRC01 Discontinuous Neutralizing (229) 
V2 CH58, CH59, 
HG107, HG120 
Linear Neutralizing (231) 
PG9 Discontinuous Neutralizing 
V3 694/98D Linear Neutralizing 
4117C, 41148D Linear Neutralizing (203) 
CH22, CH23 Linear Neutralizing (191)
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1.6.4  Methods to measure ADCC activity 
In comparison with the widely-recognized HIV-1 neutralizing antibody assay, there is no 
standard assay to detect ADCC-mediating antibodies. All the assays use antigen-coated or 
infected target cells, effector cells and an antibody preparation as inputs; but measure different 
outputs. The assays start by either coating target cells with HIV-1 peptides or proteins or 
infecting the target cells with replication-competent virus. Coated or infected target cells are 
then incubated with antibodies and effector cells, and the output is measured after a certain 
length of incubation.  
Early studies measured radioactivity read-outs from 51Cr-labelled target cells (226). While this 
method measured cell death due to ADCC, it was an expensive, laborious and insensitive assay. 
Several improved, high-throughput assays have now become available: the first, a flow 
cytometry-based fluorescent killing assay termed the “rapid fluorescent ADCC” (RFADCC) 
assay, measures the release of intracellular dyes from target cells killed by ADCC (237) after 
coating the target cells with peptides or proteins and then incubating the target cells with 
antibodies and effector cells.    
Two other assays use flow cytometry-based methods to measure the loss or addition of a 
fluorescent dye: Stratov et al. (238) developed an assay that measures the increase in expression 
of intracellular cytokines (ICS) by NK cells, which is induced by binding of the FcγRIIIa 
(CD16) receptor on NK cells to antigen-bound antibodies. Further, Pollara et al. (239) 
developed a specific and high-throughput method to measure the proteolytic activity of 
Granzyme B after its delivery into target cells, initiated by antibody recognition of viral 
antigens on the target cell membrane.  
The last two popular ADCC assays take advantage of luciferase gene expression, similar to the 
neutralizing antibody assay. The first, developed by Alpert et al. (210) uses an immortalized 
NK cell line and a target cell line which expresses Luciferase from a Tat-inducible promoter 
upon HIV-1 infection. The dose-dependent loss of Luciferase in the presence of NK cells and 
antibodies indicates the killing of infected target cells. Similarly, Pollara et al. (240) developed 
an assay which uses infectious molecular clones which contain the luciferase gene. Once target 
cells are infected with these viruses, the Tat-inducible luciferase gene is present in target cells, 
and the measurement is the same as the Alpert assay.  
One further important factor to note is the significance of the antigen used to measure ADCC. 
While peptides are non-conformational and ADCC directed towards peptide-coated target cells 
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represent antibodies which target linear peptides, the use of proteins to coat target cells is quite 
different: it is thought using these gp120/140 proteins represent the virus binding to the CD4 
molecule on the cell membrane and, thus, exposing CD4-inducible (CD4i) epitopes only 
exposed during viral entry (228). In comparison, use of infected cells is thought to expose 
epitopes present during both entry and viral budding from infected cells (240).  
1.7 Study rationale 
The RV144 vaccine trial conducted in Thailand showed modest protection from infection 
associated with V1V2-targeting ADCC-mediating nnAbs. This, together with several other 
studies, suggests ADCC responses, in combination with nAbs, may be an important response 
for an effective HIV-1 vaccine to elicit. Studying the relationship between the two types of 
antibodies will likely provide important information that aids vaccine design. While there is 
extensive information on nAbs, there is limited information on the role of ADCC in controlling 
viral populations in early infection, and how this relates to nAb responses.   
One indicator of the importance of an immune response is the ability to force immune escape. 
Escape from nAbs and CTLs has been demonstrated in many studies and is well characterised. 
However, there are only a limited number of studies on the ability of ADCC responses to force 
immune escape in the HIV-1 Env. 
This study will specifically look at HIV-1 Env evolution before, during and after the 
development of early nAb responses, to assess the impact of nAb and ADCC responses on Env 
evolution in early infection. Specifically, we would like to determine if ADCC responses exert 
immune pressure on the HIV-1 Env, which would suggest this is an important response. 
Further, the relationship between neutralizing and ADCC-mediating antibody epitopes will be 
assessed. This will elucidate the relationship between ADCC-mediating and neutralizing 
antibodies, and HIV-1 Env evolution in early subtype C infection. 
The specific objectives of this project are: 
1. To investigate the kinetics of early virus evolution in the HIV-1 Env in response to
antibody pressure in seven subtype C-infected individuals from infection to after the
detection of autologous nAbs.
2. To investigate whether Env mutations identified in early HIV-1 infection are associated
with escape from ADCC responses.
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3. To investigate the relationship between Env epitopes targeted by ADCC and nAb
responses in early HIV-1 infection.
4. To explore the breadth of ADCC responses mediated by a panel of broadly neutralizing
and non-neutralizing anti-HIV-1 monoclonal antibodies against a panel of acute/early
HIV-1 subtype C viruses.
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ABSTRACT 
The high evolution rate of HIV-1 poses one of the greatest challenges to HIV-1 vaccine 
development. In this chapter, we aimed to determine rates of escape from neutralizing 
antibodies (nAbs) following infection, and elucidate mechanisms associated with viral immune 
evasion.     
We studied seven participants of the CAPRISA 002 acute infection cohort enrolled within 56 
days of infection and followed for 6 months. Viral diversification in known nAb epitopes was 
quantified using a deep sequencing approach, and escape residues were confirmed using 
pseudovirus neutralization assays. Cell-cell transmission inhibition assays were performed as 
a potential mechanism by which the virus may escape nAb responses without having to mutate. 
Following nAb responses, there was a significant drop in the relative frequency of wildtype 
(WT) virus.  However, when controlling for changes in viral load (VL) over time, we observed 
that the WT load (frequency of the WT residue x total VL) remained relatively stable in three 
participants despite an effective nAb response, while the escape mutant load increased. Our 
data revealed that early nAbs were unable to inhibit cell-cell transmission as efficiently as free 
virus-cell transmission, and the incorporation of escape mutations resulted in further loss of 
inhibition of both free virus-cell and cell-cell transmission.  
These results demonstrate that early nAb responses may not effectively clear viral populations. 
While changes in the viral genome is a dominant pathway to nAb escape, cell-cell transmission 
provides an alternative pathway. As these nAbs were less effective at inhibiting cell-cell 
transmission, this provides a potential mechanism whereby HIV-1 can escape early autologous 
nAbs. These results suggest that other antibody effector functions such as ADCC, which can 
target infected cells, may be important to elicit in a protective HIV-1 vaccines.   
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2.1 Introduction 
One of the major goals of the HIV-1 vaccine field is to discover a vaccine which elicits 
protective nAbs. However, the high diversity of HIV-1 in the Envelope (Env), which is the 
target of nAbs, makes this a challenge. The  diversity of HIV-1 is partially the result of rapid 
escape from immune responses, typically through point mutations in the nAb epitope, and 
lengthening of the variable loops and glycosylation changes which serve to shield nAb epitopes 
(56, 161, 165). This results in contemporaneous viruses that are less sensitive to autologous 
neutralization than earlier viruses (158, 159, 164). The consequence is that the nAb response 
must constantly catch-up to the escaped HIV-1, which would compromise protection from an 
HIV-1 vaccine.  
While most studies have observed rapid and complete escape from nAbs, particularly in early 
infection, there have been a few exceptions. Two studies by Bar et al. and Moore et al. 
demonstrated persistence of the WT, nAb sensitive virus in early infection (each in one 
participant) (164, 241). In both studies, the WT remained detectable in all time-points tested, 
up to several months after the detection of nAbs, but still decreased 1-2 logs in quantity 
suggesting nAb pressure was still substantial. If the WT virus is persisting, the mechanism 
whereby it avoids nAb detection remains unclear. Further, the implication of nAb sensitive WT 
virus persistence is unknown.  
Numerous studies have shown nAbs are less efficient at inhibiting cell-cell transmission than 
free virus-cell transmission, including broadly neutralizing antibodies (bnAbs), implicating 
cell-cell transmission as a possible mechanism whereby WT virus may avoid detection (242–
248). Cell-cell transmission occurs via the formation of virological synapses (249–251), and is 
faster and more efficient in vitro than infection from cell-free virus (252–254). The efficient 
formation of this synapse may result in steric hindrance, preventing antibodies from accessing 
the synapse. 
Here, we used a deep sequencing approach to quantify viral diversification in the known nAb 
epitope in response to early anti-HIV-1 antibody development from infection till after the 
detection of nAbs. Using pseudovirus neutralization assays, we then determined the kinetics of 
nAb escape, at a residue level. When considering changes in VL over time, we observed that 
following nAb responses, the WT load (frequency of the WT residue x total VL) remained 
relatively stable, while the escape load (frequency of the mutant x total VL) increased. 
Consequently, we explored cell-cell transmission as one mechanism by which the WT virus 
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population (viruses which contained the original, WT residue at the site of nAb escape) may 
be maintained. Our data revealed that nAbs were unable to inhibit cell-cell transmission as 
effectively as free virus-cell transmission, and the incorporation of escape mutations resulted 
in further loss of inhibition of both free virus-cell and cell-cell transmission. 
2.2 Methods 
2.2.1 Ethics statement 
The CAPRISA 002 acute infection study received ethical approval from the Universities of 
KwaZulu-Natal (E013/04), Cape Town (025/2004), and the Witwatersrand (MM040202). All 
participants in this study provided written informed consent for study participation. This study 
further received ethical approval from the University of Cape Town (430/2014) as a sub-study 
of the CAPRISA acute infection study. 
2.2.2 CAPRISA 002 acute infection cohort participants 
The CAPRISA 002 acute infection cohort, described previously (162, 255), was established in 
2004 and recruited recently HIV-1 infected women, from Durban, KwaZulu-Natal, South 
Africa, prospectively. HIV-1-infected participants were recruited within 3 months of a previous 
HIV-1 negative test. Following detection of infection, plasma samples were taken weekly for 
3 weeks, fortnightly until approximately 3 months post infection, monthly until approximately 
1 year post infection, and quarterly thereafter.  The time of infection was estimated as the mid-
point between the last HIV-1 negative sample and the first HIV-1 positive sample, or 14 days 
prior to the first HIV-1 positive sample if the sample was RNA-positive, seronegative. Each 
participant was monitored for CD4 count and viral load. 
2.2.3 Cell lines 
TZM-bl cells (159) were obtained from the NIH AIDS Research and Reference Reagent 
Program (NIH ARP, catalogue number 8129, contributed by John Kappes and Xiaoyun Wu). 
The 293T cell line was obtained from Dr George Shaw (University of Pennsylvania, 
Philadelphia, PA). All adherent cell lines were cultured at 37 °C, 5% CO2 in DMEM containing 
10% heat-inactivated Fetal Calf Serum (FCS) (Biochrom) with 50 µg/mL Gentamicin (Lonza) 
and disrupted at confluency by treatment with 0.25% trypsin in 1 mM EDTA (Lonza). 
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2.2.4 Peripheral blood mononuclear cells 
Human primary peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient 
from buffy coats obtained from healthy HIV-1 seronegative donors. Buffy coats were supplied 
by the Western Province Blood Transfusion Services. PBMC were cultured in RPMI 1640 
growth medium supplemented with gentamicin (50 U/mL), L-glutamine (2 mM) and 10% FCS 
(Biochrom) (subsequently referred to as R10), as well as interleukin-2 (IL-2) (30 U/mL) 
(Roche). The cells were stimulated by culturing in R10-IL-2 medium containing 
phytohemagglutinin (PHA) (2.5 μg/mL) (Sigma) for 72 h. After 72 h, the medium was removed 
and the cells were placed into culture with R10 growth medium containing IL-2 (30 U/mL) and 
used immediately. 
2.2.5 Deep sequencing library preparation and data processing 
RNA extraction, cDNA synthesis and subsequent amplification were carried out using the 
primer ID method as described previously (256, 257), with the following modifications: cDNA 
synthesis primers were designed to bind to the C2 (HxB2: 6907-6883), C3 (HxB2: 7343-7318) 
or C5 (HxB2: 7655-7632) regions of the HIV-1 env respectively (depending on the region to 
be amplified) (all primer sequences can be found in Appendix A4). First-round amplification 
primers were designed to bind to the C1 (HxB2: 6654-6674), C2 (HxB2: 6950-6973) or C3 
(HxB2: 7114-7135) regions respectively. This allowed amplification of the C1C2, C2C3 or 
C3C5 regions depending on the primer set used. Raw reads were processed using a local 
instance of Galaxy (258–260), housed within the University of Cape Town High-Performance 
Computing core. Read quality was assessed using fastqc 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Short reads (<150 bp), and low-
quality data, were filtered out using the Filter FASTQ (version 1.0.0) tool (258) with a 
minimum quality of Q35 for 3′ base trimming. Forward and reverse reads were merged using 
PEAR (261). A custom python script (written by Phillip Labuschagne, UCT) was used to bin 
all reads containing an identical Primer ID tag, to align the reads within each bin using MAFFT 
(262) and to produce a consensus sequence based on a majority rule. Sequences with a Primer
ID that was represented in fewer than three reads were discarded, along with and those 
containing degenerate bases. The resulting consensus sequences were then used to generate 
codon aligned nucleotide and amino acid alignments using MACSE (263) and viewed using 
BioEdit (Version 7.1.11) (264). The Hamming distance was calculated using a custom script 
(adapted from a script written by Dr Colin Anthony, UCT), adjusted such that deletions of any 
size resulted in a score of one, and normalised to the distance of the region sequenced. 
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Magnitude of selection was calculated using FUBAR (265) in the HyPhy 2.2.1 software 
package (266). 
2.2.6 Jensen-Shannon divergence 
Jensen-Shannon divergence (DJS) is a measure of dissimilarity between probability 
distributions that was introduced by Lin (267) to alleviate the limitations associated with 
relative entropy, and can take into account changes in distributions between two time points. 
DJS between the two discrete probability distributions p = (p1, …, pn) and q = (q1, …, qn) is 
defined as follows: 
DJS(𝑝, 𝑞) =  
DKL (𝑝, 𝑎) +  DKL (𝑞, 𝑎)
2
where a = (p + q)/2 is the average of p and q, and DKL (x,y) is the relative entropy between x 
and y. The values of DJS are normalized to lie between 0 and 1. 
DJS can be expressed using entropy (H) with the following formula: 
DJS(𝑝, 𝑞) = H (
𝑝 + 𝑞
2
) −  
H(𝑝) + H(𝑞)
2
DJS was measured using a custom script written by Dr Colin Anthony (UCT). 
2.2.7 Cloning gp160, mutagenesis and pseudovirus production 
PCR amplification of HIV-1 env genes was done using the single-genome amplification (SGA) 
approach previously described (268). The second-round PCR reaction was repeated using the 
high-fidelity Platinum Taq DNA Polymerase (Invitrogen), together with 0.2 mM dNTPs 
(Invitrogen), 4 µM of Env 1A-Rx (5'- CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA 
-3') and EnvN (5’- CTGCCAATCAGGGAAAGTAGCCTTGT -3') in a final volume of 20 µL.
Amplicons were cloned into the directional vector pcDNA3.1(+) (Invitrogen) per the 
manufacturer’s instructions. Site-directed mutagenesis was performed using the Stratagene 
QuickChange II kit (Stratagene). Env pseudoviruses were obtained by co-transfecting the env 
plasmid with pSG3ΔEnv (159) in 293T cells using PolyFect transfection reagent (Qiagen). 
Pseudovirus-containing supernatants were harvested 48 h following transfection and clarified 
by 0.45 µm filtration and adjusted to 10% FCS (Biochrom). The 50% tissue culture infectious 
dose (TCID50) for each pseudovirus preparation was determined by infection of TZM-bl cells 
as previously described (162, 269). 
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2.2.8 Neutralization assay 
Neutralization was measured, as previously  described (162), by a reduction in luciferase gene 
expression after single round infection of TZM-bl cells with Env pseudo or infectious viruses. 
All experiments were repeated two to three times. Titers were calculated as the mean reciprocal 
plasma dilution which resulted in a 50% reduction (ID50) of the relative light units (RLU). 
2.2.9 Construction of HIV-1 infectious molecular clones and virus preparation 
HIV-1 Infectious Molecular Clones encoding the env (Env-IMC) for early viruses CAP210 TF, 
CAP255 2.00.5 and CAP257 2.00.Luc, as well as mutant viruses CAP210 TF A161V and 
CAP210 TF V208I, were constructed as previously described in the Ochsenbauer laboratory 
(270) (Appendix A2). Env-IMCs for CAP239 TF and CAP239 TF L278S were constructed at
UCT (D Mielke) (Appendix A2). All Env-IMCs expressed Renilla luciferase reporter gene 
under the control of the HIV-1 Tat protein, and preserved all nine viral open reading frames. 
Replication-competent viruses were obtained by transfecting the Env-IMC plasmid in 293T 
cells using PolyFect transfection reagent (Qiagen). Virus-containing supernatants were 
harvested 48 h following transfection, clarified by 0.45 µm filtration and adjusted to 10% FCS 
(Biochrom). The TCID50 for each IMC preparation was determined by infection of TZM-bl 
cells as previously described (162, 269). 
2.2.10 Infection of PBMCs 
Stimulated healthy PBMCs from four donors were depleted of CD8+ T cells using MACS 
human CD8 microbeads (Miltenyi Biotec) per the manufacturer’s recommendations, and 
pooled in a ratio of 1:1:1:1. Five million pooled, CD8-depleted PBMCs were then centrifuged, 
the supernatant removed and the cells resuspended in 1 mL of virus preparation. The cells were 
then spinoculated (1000 x g) for 2 h at 32 °C. After spinoculation, 2 mL of R10 supplemented 
with IL-2 (30 U/mL) (Roche) was added. Growth medium was replaced after 24 h, and infected 
cells were grown at 37 °C, 5% CO2 for a further 72 h. PBMCs from the same four donors were 
used in each experiment and subsequent repeats.  
2.2.11 Assessment of viruses used in cell-cell inhibition assays 
We used the method developed by Abela et al. (242), which utilizes the dependence of R5-
tropic viruses on polycationic supplements in cell culture medium to infect TZM-bl cells as 
cell-free virions, to measure the inhibition of cell-cell transmission.  
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To determine if viruses could be used in the cell-cell inhibition assay, viruses were tested for 
dependence on the polycation diethylaminoethyl-Dextran (DEAE-Dextran) to infect TZM-bl 
cells as free virus inoculum. Serial dilutions of free viruses were titrated over TZM-bl cells 
(104 cells per well) in culture medium in the presence or absence of DEAE-Dextran (20 µg/mL) 
(Sigma) for 48 h. Only viruses that resulted in at least one log reduction of infectivity over the 
linear range in the absence of DEAE-Dextran, when compared with infectivity in the presence 
of Dextran, were used in the cell-cell inhibition assay (Appendix A1, Figure A1.3). Cell-free 
virus input was chosen to yield infectivity corresponding to 100 000 – 125 000 RLUs (within 
the linear range) per well in the absence of inhibitors.  
To assess the ability of virus from infected PBMCs to infect TZM-bl cells, infected PBMCs 
were washed three times with PBS (Lonza) and titrated on TZM-bl cells (104 cells per well) in 
culture medium in the presence and absence of DEAE-Dextran for 48 h (Appendix A1, Figure 
A1.4). Input of infected PBMCs for the cell-cell inhibition assay was chosen such that the 
resulting infection of TZM-bl cells was within the same range as the free virus infections 
(infectivity corresponding to 100 000 – 125 000 RLUs) and within the linear range of infection. 
To ensure cell-cell transmission was in the linear range of the assay, a titration of donor input 
cells was included in each experiment. 
To ascertain that residual infectivity from free virus secreted by infected PBMCs was not 
interfering in the discrimination between free virus-cell and cell-cell infection in the cell-cell 
inhibition assay, we tested supernatants from PBMCs for infectivity of TZM-bl cells. The 
number of PBMCs corresponding to infectivity 100 000 – 125 000 RLUs (and calculated from 
the titration of infected PBMCs in the presence and absence of DEAE-Dextran, above) was 
added to HeLa cells (CD4/CCR5 negative) (104 cells per well) in culture medium to mimic the 
conditions of the infected PBMCs/TZM-bl infection system. Supernatant was harvested at 12 
h, 24 h and 48 h and added to TZM-bl cells (104 cells per well) for 48 h (Appendix A1, Figure 
A1.5). Only viruses with residual infectivity of TZM-bl cells which resulted in < 10% above 
cell background at the determined input number of infected PBMCs were used in the cell-cell 
inhibition assay. 
2.2.12 Cell-cell inhibition assay 
Similar to Abela et al. (242), four days after the infection of PBMCs infection, previously 
collected plasma from CAPRISA 002 participants was serially diluted (3 x starting at 1:45). 
Infected PBMCs were washed three times with PBS to remove free virions and then the 
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appropriate number of infected PBMCs were incubated with plasma for 1 h before co-culturing 
with TZM-bl cells (104 per well) in the absence of DEAE-Dextran. 48 h post infection, cells 
were lysed and luciferase gene production was measured upon addition of Firefly Luciferase 
substrate (Promega). Experiments were repeated two to three times. Percentage inhibition was 
determined by calculating the mean inhibition at each dilution, based on data from two to three 
independent experiments and plotted on GraphPad Prism (v6.0).  
2.3 Results 
2.3.1 Defining the virus that established clinical infection 
Seven participants from the CAPRISA 002 acute infection cohort, with a known target and 
timing of the first nAb responses to the HIV-1 Env, were selected (Table 2.1). In each case, the 
first nAb target was limited to one region on the Env, and varied from participant to participant 
(either V2, C3, C3V4, V4 or the CD4-binding site (CD4bs)), with the timing of the response 
ranging from 9 to 19 weeks post infection (wpi). To investigate the impact of nAbs on the early 
evolution of the HIV-1 Env in the region first targeted by nAbs, samples were deep sequenced 
using  the Primer ID method (256), which allows for  accurate sequencing and quantitation of 
viral populations. Samples from five participants were sequenced as part of this thesis, and 
sequences for two participants were provided by Dr Colin Anthony (UCT). An average of 8 
time-points (5-10) per participant were sequenced. A consensus sequence was generated from 
≥ 3 sequences with identical primer IDs by the majority rule, generating an average of 1493 
consensus sequences (51-12842) per time-point.  
Table 2.1. Target and timing of the initial autologous nAb responses in seven CAPRISA 
002 participants. 
Participant Envelope Target Timing (nAbs first detected/ wpi) Reference 
CAP45 C3V4 9 (164) 
CAP63 V4 7 (164) 
CAP88 C3 15 (164) 
CAP177 C3 19 (164) 
CAP210 V2 16 (164) 
CAP239 CD4bs 13 
Unpublished data 
(D Mielke) 
CAP255 C3 15 (271)
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To determine the multiplicity of infection, we used Poisson-Fitter on the sequences generated 
from the first time-point post infection (272).  Sequences from six of the seven participants had 
a star phylogeny, suggesting single variant transmission, and one participant, CAP255, was 
infected with two variants at enrolment (8 wpi) (Appendix A1, Figure A1.1). Furthermore, for 
one of these participants with a single variant at enrolment (2 wpi), CAP177, a second variant 
was detected at 4 wpi (Appendix A1, Figure A1.2) (273).  
Together the data suggests that in five cases, a single virus was responsible for clinical 
infection, and two variants for the remaining two (Appendix A1, Table A1.1). 
2.3.2 Divergence observed prior to the detection of nAbs 
To investigate the relationship between HIV-1 Env evolution and early nAb responses, we 
assessed divergence from the transmitted/founder (T/F) virus. Divergence was calculated as 
the average normalised Hamming distance (adjusted such that deletions were calculated as one 
event) from the T/F sequence. For participants with a single variant responsible for clinical 
infection, the T/F virus was defined as the consensus sequence from the first time-point 
sequenced. The two participants with multiple founders were excluded from this analysis as 
the presence of multiple founders and recombinants confounded the estimates of divergence.  
To determine the role of nAbs on viral divergence, we measured the rate of divergence from 
the T/F sequence to sequences generated from the last nAb negative time-point (% normalised 
Hamming distance per month), and then from the last nAb negative time-point to the time-
point of first detectable nAbs. In all five individuals, there was limited divergence prior to nAbs 
(mean: 0.012% per month) and a large increase concurrent with detection of nAbs (mean: 
0.542% per month) (Table 2.1, Figure 2.1). In CAP45 C3C5, the rate of divergence prior to 
detectable nAbs was 0.027% per month, and increased 10-fold to 0.288% per month after nAbs. 
In CAP88 C2C3, the rate of divergence increased 89-fold from 0.021% per month to 1.867% 
per month, after nAbs were detected. In CAP63, the rate of divergence in the C3C5 increased 
1.8-fold from 0.215% per month prior to detectable nAbs to 0.384% per month after nAbs were 
detected. In CAP210 C1C2, we observed a 4.4-fold increase in the rate of divergence from 
0.040% per month prior to nAbs to 0.174% per month when nAbs were detected. Lastly, in 
CAP239 we investigated divergence from the consensus sequence in three regions (C1C2, 
C2C3 and C3C5) of the Env, as the first wave of nAbs targeted the CD4bs. No increase in the 
rate of divergence was detected in C1C2, but a 5.1-fold increase was detected in C2C3 (0.039% 
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per month to 0.198% per month) and an 11-fold increase in the rate of divergence in C3C5 
(0.077% per month to 0.879% per month). 
Table 2.2. Rate of divergence in the region targeted by the initial nAb response before 
































CAP45 C3C5 5 0.027 9 0.288 10 
CAP63 C3C5 4 0.215 7 0.384 1.8 
 CAP88 C2C3 11 0.021 13 1.867 89 







C2C3 0.039 0.198 5.1 
C3C5 0.077 0.879 11 
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Figure 2.1. Divergence from T/F sequences in regions targeted by the initial autologous nAb 
responses in five individuals. Average hamming distances, normalised to the nucleotide length of each 
amplicon, were calculated for each time-point (black line). Bubble sizes indicate the size of the viral 
population, scaled by viral load, and bubble positions indicate viral populations with various degrees of 
divergence from the T/F sequence. The shaded region indicates the time from which the initial nAb 
response was first detected (IC50). Hamming distances were adjusted so deletions were calculated as 
one event.
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2.3.3 Positions exhibiting high Jensen-Shannon divergence are in the nAb epitope 
In three individuals (CAP63, CAP210 and CAP239), there was evidence of divergence prior 
to detection of nAbs (Figure 2.1). To evaluate these changes at each amino acid position, we 
calculated the Jensen-Shannon divergence (DJS) over time. DJS was used instead of Shannon 
entropy as it allows the measurement of dissimilarity of probability distributions between time-
points (267). Examination of these three participants revealed several sites with raised DJS prior 
to and concurrent with the emergence of the nAb response (Figure 2.2).  
We found changes occurring prior to the detection of nAb responses at 3, 4 and 2 weeks prior 
to detectable nAbs in CAP63, CAP210 and CAP239, respectively. In CAP63, increased DJS 
was observed at one site in V4 (397) (Figure 2.2). The mutation (P397S), when introduced into 
the T/F sequence, conferred resistance to nAbs (Figure 2.3), confirming nAb escape. In 
CAP210, elevated DJS was observed at two sites: one in the V2 of the Env (161) and the other 
at the start of the C2 (208) (Figure 2.2). One mutation (A161V) resulted in complete resistance 
to the nAb response, while the other mutation (V208I) resulted in partial resistance (Figure 
2.3). In the third individual, CAP239, low DJS was observed at one site (375) five weeks prior 
to nAb detection, due to a mutation (S375L) (Figure 2.2, white arrow). However, we could not 
assess escape as we were not able to produce functional pseudoviruses incorporating the 
mutation. 
As expected, most amino acid changes observed were concurrent with or after the detection of 
nAbs (Figure 2.2). In CAP63, numerous variants with deletions across sites 395-410 were 
observed, explaining the DJS observed in a wide number of contiguous sites in the region. In 
CAP210, there was very low DJS observed at sites other than at positions 161 and 208. Further, 
DJS was first observed in CAP239 at position 463 at the time of nAb detection, and then again 
at several sites across the gp120 six weeks later, including in the C1, C2 and C5 (positions 106, 
278, 459 and 463.02) (Figure 2.2, blue arrows). Three of the mutations observed at these sites 
(K106E, L278S and K463E) were incorporated into the T/F virus and tested for neutralization 
sensitivity. All three mutants were resistant to the initial nAb response, with K463E and L278S 
becoming partially resistant to nAbs by 22 wpi, while K106E remained resistant until 29 wpi 
(Figure 2.3).  
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Figure 2.2. Jensen-Shannon Divergence plots of the region targeted by initial autologous nAb 
responses in three individuals: CAP63, CAP210 and CAP239. DJS for each position at each time-
point sequenced was calculated. White arrows indicate sites exhibiting high Djs prior to detectable 
nAbs:  one site (position 397) in CAP63, two sites (161 and 208) in CAP210, and one site in CAP239 
(375).  Five sites (106, 278, 459, 463 and 463.02) in CAP239 were identified as a second wave of sites 
which diverged later (blue arrows). The white dotted line indicates the time from which the initial nAb 
response was first detected (IC50).  
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Figure 2.3. Autologous neutralization titer (ID50) for T/F (blue) and escape mutants in three 
participants: CAP63, CAP210 and CAP239. 
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2.3.4 Stable presence of wildtype residues targeted by first nAbs 
Having confirmed sites targeted by nAbs in early infection in three participants, we used deep 
sequencing to investigate the evolution of viral populations and how they adapted to nAb 
responses. In all three individuals, there was a significant decrease in the relative frequency of 
the WT residue, due to the emergence of nAb escape mutations.  
In CAP63, WT frequency (P397) decreased from 99.9% at 2 wpi (prior to the detection of 
nAbs) to 27% at 4 wpi, and 12% at 7 wpi (the time at which nAbs became detectable), while 
the relative frequency of the mutant (P397S) rose proportionally (Figure 2.4A). However, there 
was an increase in viral load (VL) at the time nAbs were detected, which meant the change in 
the relative frequency of the WT residue did not translate to a decrease in the WT load (WT 
frequency x total VL). In fact, the WT load remained relatively stable, ranging from 75,545 
copies/mL at 4 wpi (prior to detection of nAbs) to 79,101 copies/mL at 7 wpi, 86,990 
copies/mL at 9 wpi and 99,695 WT copies/mL at 11 wpi (after nAbs are detected).  
The relative decrease in WT virus was also observed in CAP210, where the WT (A161) 
frequency decreased from 99% at 7 wpi and 89% at 12 wpi (prior to the detection of nAbs) to 
19% at 16 wpi (when nAbs become detectable) (Figure 2.4B). Similarly, the WT load remained 
relatively stable, or even increased, varying from 52,721 copies/mL at 7 wpi and 44,756 
copies/mL at 12 wpi (prior to the detection of nAbs) to 94,940 copies/mL at 16 wpi (at the time 
nAbs become detectable). 
Lastly, in CAP239 toggling at the first residue targeted by nAbs (E463) was detected, with 
E463 decreasing from 99% at 11 wpi (prior to the detection of nAbs) to 62% at 13 wpi (the 
time at which nAbs are detected), replaced by K463 (31%), G463 (3.8%) and D463 (1.7%) 
(Figure 2.4 C). In CAP239, due to an increase in overall VL, there was a 0.5 log increase in 
WT load following detection of nAbs (15,942 copies/mL at 11 wpi (before nAbs) to 34,891 
copies/mL at 13 wpi). This pattern was even more evident in the second wave of escape mutants 
observed in CAP239, which arose 6 weeks after the detection of nAbs. In the C1, K106 
decreased from 98% at 13 wpi (when nAbs are detected) to 78% at 19 wpi and 37% at 22 wpi, 
while E106 increased equivalently. At the same time, when considering the VL, the WT load 
dropped by 0.5 log (from 55,502 copies/mL at 13 wpi to 18,353 copies/mL at 19 wpi), but rose 
to 82,532 copies/mL at 22 wpi. This was further observed to be the case at position 278 in the 
C2. L278 dropped from 100% at 13 wpi to 57% at 19 wpi and 10% at 22 wpi, suggesting strong 
negative selection. However, the WT load decreased from 56,400 to 13,394 copies/mL between 
13 and 19 wpi, and then remained relatively stable at 22,705 copies/mL at 22 wpi.  
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Figure 2.4. Relative frequencies and loads of wildtype and mutant residues. The relative frequencies are shown as a percentage of consensus sequences 
generated; and WT and mutant loads calculated as the WT or mutant relative frequency x total VL (number of viral copies/variants per mL of blood). The 
WT is represented by a blue line and mutant residues by red, green, orange, yellow lines. Confirmed escape mutations evaluated: P397S in V4 of the Env in 
CAP63 (A), A161V (in V2) and V208I (in C2) of the Env in CAP210 (B) and K106E (in C1), L278S (in C2) and K463E/G/D/- (in C5) of the Env in CAP239 
(C). The shaded region indicates the time from which the initial nAb response is first detected (IC50). 
Chapter 2 – Early neutralizing antibody pressure and viral evolution 
46 
2.3.5 Mutant loads increased due to an increase in total viral load 
An analysis of viral population dynamics at the regions first targeted by the nAb response showed 
that the WT load did not decrease following nAb responses. Instead, we saw a substantial increase 
in the mutant load (mutant frequency x total VL), due to an increase in VL in each participant at 
the time of nAb detection. In CAP63, the VL increased from 277,000 copies/mL to 640,000 
copies/mL; and in CAP210, an increase in VL from 50,100 copies/mL to 496,000 copies/mL was 
observed. In CAP239, two increases were observed: an increase from 16,100 copies/mL to 56,400 
copies/mL at the detection of nAbs, and an increase from 23,600 copies/mL to 224,000 copies/mL 
concomitant with detection of the second wave of nAb escape (Figure 2.4). In all participants, the 
emergence of nAbs was after acute infection, where the VL was on the decline. 
This is suggestive of strong positive selection driving an increase in escape variant copies, as 
opposed to negative selection acting against the WT residue. To confirm this, we quantified the 
magnitude of selection pressure on these sites, using FUBAR (265). A value of β-α=0 was used to 
represent neutrality (where β denotes the rate of non-synonymous mutations and α signifies the 
rate of synonymous mutations) and β-α>1 as a working definition of strong positive selection 
pressure (as previously described by Murrell et al. (265)).  
Figure 2.5. Magnitude of selection at sites in the Env regions targeted by nAbs in three participants. 
The magnitude of selection was calculated, using FUBAR (265), at each time-point sequenced for each site 
identified: 397 in the V4 of CAP63 (A), 161 and 208 in the C1C2 of CAP210 (B) and 106, 278 and 463 in 
the C1C2, C2C3 and C3C5 of CAP239, respectively (C). β denotes the rate of non-synonymous mutations 
while α signifies the rate of synonymous mutations. β-α>1 was used as a working definition of strong 
positive selection (dotted line). The shaded region indicates the time from which the initial nAb response 
is first detected (IC50). 
Chapter 2 – Early neutralizing antibody pressure and viral evolution 
47 
We observed strong positive selection pressure in CAP63 at position 397 at 4 wpi (β-α = 14.49), 
concomitant with the increased rate of divergence from the T/F sequence, increased DJS at position 
397 and the P397S shift (Figure 2.5 A). However, this positive selection shifted to strong negative 
selection soon after nAbs became detectable (β-α = -9.79 at 9 wpi, -12.15 at 11 wpi and -17.29 at 
14 wpi), presumably as the nAb response developed and the virus toggled to obtain the best 
pathway of escape from the nAb response. 
In CAP210, we also observed strong positive selection prior to the detection of nAbs at sites 161 
and 208, concurrent with the increased rate of divergence from the T/F sequence and detection of 
increased DJS (Figure 2.5 B). While selection pressure remained stable at 208, there was a 
considerable increase in the magnitude of positive selection at position 161 (β-α = 1.66 at 12 wpi, 
versus 6.27 at 16 wpi) concomitant with detection of nAbs at 16 wpi.  
Finally, strong positive selection was observed in CAP239 concomitant with development of 
nAbs. At position 463, the first site of nAb escape in CAP239, selection pressure was close to 
neutral prior to detection of nAbs (β-α = -0.67 at 8 wpi, -1.51 at 11 wpi), but at 13 wpi (the time 
at which nAbs were detected) an elevated magnitude of positive selection was detected (β-α = 
6.64) (Figure 2.5 C). The two sites which shifted later (K106E and L278S) exhibited similar 
results. The magnitude of positive selection increased notably between 13 wpi (β-α = 1.49 at 
position 106, -0.61 at position 278) and 19 wpi (β-α = 6.30 at position 106, 4.44 at position 278). 
2.3.6 Neutralization sensitive viruses persist by evading plasma antibodies through cell-
cell transmission 
One mechanism for persistence of the WT residue is cell-cell transmission of the virus, allowing 
evasion from nAbs and providing a continual source of WT viruses. Accordingly, we investigated 
the ability of plasma antibodies to inhibit free virus-cell and cell-cell transmission.  For the cell-
cell inhibition assay, viruses had to be DEAE-dextran dependent, infect PBMCs to a sufficient 
level, and have minimal background from viruses secreted by PBMCs during the assay. Of the 
seven Env-IMCs encoding acute/early envs we had available, viruses produced from four (CAP210 
TF, CAP239 TF, CAP255 2.00, CAP257 2.00) met these criteria (Appendix A1, figures A1.3-
A1.5). We tested the ability of autologous plasma from these four participants from two different 
time-points (6 months post infection (mpi) and 2 years post infection (ypi)) to inhibit free virus-
cell and cell-cell transmission.   
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Figure 2.6. Autologous plasma inhibition of free virus-cell (red) and cell-cell transmission (blue) of 
acute/early viruses.  Inhibition curves of free virus-cell or cell-cell transmission (CAP210 TF, CAP239 
TF, CAP255 2.00, CAP257 2.00; each row representing a different virus) using autologous plasma (three-
fold serial dilution starting at 1:45) from 6 mpi (left column) or 2 ypi (right column) (A). The % inhibition 
of free virus-cell and cell-cell transmission by plasma from 6 mpi (left bars) and 2 ypi (right bars) at 1:45 
dilution with standard error (B). 
Autologous plasma inhibition was compared by determining the % inhibition of free virus-cell 
transmission to cell-cell transmission at 1:45 dilution (Figure 2.6). At 6 mpi, antibodies could 
inhibit 100% of free virus-cell transmission in three participants (CAP239, CAP255, CAP257), 
and 75% of free virus-cell transmission in one participant (CAP210) (Figure 2.6 A, B). Inhibition 
of cell-cell transmission was substantially lower in all four participants, with maximum autologous 
cell-cell inhibition ranging from 21% (CAP210, CAP239, 255) to 45% (CAP257) (Figure 2.6 A, 
B). 
We then used plasma from chronic infection (2 ypi) to establish if a more developed antibody 
response could better inhibit cell-cell transmission. Antibodies from plasma at this time-point 
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could efficiently inhibit free virus-cell transmission at 1:45 dilution (100% of free virus-cell 
transmission was inhibited in CAP235, CAP255, CAP257), and similar to the six month timepoint, 
the CAP210 virus was more resistant to neutralization, with 95% inhibited at 1:45 dilution (Figure 
2.6 A, B). Chronic plasma had improved efficiency of inhibition of cell-cell transmission. However 
complete inhibition was not achieved, even at the lowest dilution (1:45) (inhibition of the 
autologous virus ranged from 24% by CAP210 plasma to 68% by CAP257) (Figure 2.6 A, B). 
2.3.7 Escape mutations increase resistance of early viruses to inhibition by plasma 
antibodies 
Having established a reduced inhibition of cell-cell transmission of the WT virus by autologous 
plasma antibodies, we wished to determine the effect of escape mutations on plasma inhibition of 
cell-cell transmission. We incorporated mutations, identified by deep sequencing, into the 
respective Env-IMC for two participants (A161V and V208I in CAP210; L278S in CAP239), and 
tested the ability of autologous plasma to inhibit free virus-cell and cell-cell transmission of the 
mutant viruses at a dilution of 1:45. 
In CAP210, both mutations resulted in a decrease in free virus-cell transmission at 6 mpi (75% 
inhibition of the WT virus, in comparison with 40% inhibition of A161V and 59% inhibition of 
V208I) and cell-cell transmission (20% inhibition of the WT virus versus 11% inhibition of A161V 
and 0% inhibition of V208I) by plasma antibodies at 1:45 dilution (Figure 2.7). By 2 ypi, while 
there was still a decreased inhibition of the mutant viruses, plasma antibodies had developed to 
inhibit free virus-cell transmission to almost comparable levels (95% inhibition of the WT virus 
contrasted with 88% inhibition of A161V and 79% inhibition of V208I). However, inhibition of 
cell-cell transmission was still greatly reduced (24% inhibition of the WT virus versus 14% 
inhibition of A161V and 2% inhibition of V208I). 
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Figure 2.7. Inhibition by autologous plasma of free virus-cell and cell-cell transmission of WT and 
mutant viruses from CAP210 (A) and CAP239 (B).  Autologous plasma was assayed against the T/F and 
mutant viruses for CAP210 (WT, A161V, V208I) and CAP239 (WT, L278S). Viruses were assayed against 
plasma from 6 mpi or 2 ypi  
A similar pattern was observed in CAP239. At 6 mpi, plasma antibodies could inhibit 100% free 
virus-cell transmission and 22% cell-cell transmission of the WT virus, while only inhibiting 57% 
of free virus-cell transmission and 0% of cell-cell transmission of the L278S mutant virus (Figure 
2.7). Plasma from 2 ypi could inhibit 100% free virus-cell transmission of both the WT and L278S 
mutant viruses at 1:45 dilution, while cell-cell transmission was reduced (50% of WT viruses were 
inhibited versus 34% of L278S mutant viruses). 
2.4 Discussion 
Using a deep sequencing approach to estimate the kinetics of total viral populations over a six-
month period, we showed the WT virus persisted at a relatively stable copy number despite nAb 
B A 
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responses. While previous studies have reported the persistence of WT virus in the face of nAb 
responses (223, 241), the relative stability of this population may not have been observed using 
conventional Sanger sequencing (Moore et al.) or 454 pyrosequencing (Bar et al.) due to the low 
relative frequency of the WT virus, which could be a result of outgrowth of the escape virus 
associated with a concomitant increase in VL. These early nAbs, while highly effective against 
free viruses, were only partially effective at blocking cell-cell transmission, providing a potential 
mechanism whereby the WT virus may persist. These results highlight the possible limitations of 
antibody neutralization in a protective HIV-1 vaccine, and indicate the likely importance of 
antibody effector functions such as ADCC, which can target infected cells and potentially prevent 
cell-cell transmission. 
Several studies have suggested that persistent minority variants play a role in engaging and 
promoting certain lineages of nAbs. Bhiman et al. showed that low frequency variants in the V2 
effectively engaged bnAb precursors, suggesting these variants were important in promoting the 
CAP256-VRC26 bnAb lineage (274). In contrast, Wibmer et al. found a rare persistent glycan-
free V5 virus lineage (< 5%) which was likely responsible for initiating a nAb with narrow breadth 
(257). Our study found that while the relative frequency of these viruses may have been low, the 
total VL remained high, thus providing a high dose, persistent exposure of the host immune system 
to the WT virus, which may in turn potentially enhance maturation of the immune response. 
There were limited changes detected prior to the development of nAbs in the regions we 
sequenced. We observed no evidence of immune escape prior to the detection of nAbs in two 
individuals and low level of nAb escape two to four weeks prior to the detection of nAbs in the 
remaining three participants, consistent with a previous study by Bar et al., which found evidence 
of very low levels of escape variants (0.2-1.1%) prior to detectable nAbs in two individuals of the 
CHAVI acute infection cohort (241). Their results suggest that there is very limited to no selection 
pressure prior to the development of nAbs in the region first targeted by these antibodies. 
In comparison, development of nAbs resulted in rapid viral divergence in all five participants, with 
evidence of residue toggling at the sites of escape. Despite this, the WT population size remained 
constant when considering changes in VL in three participants; while the escape variant population 
size increased considerably. While it is difficult to distinguish negative (purifying) and positive 
(adaptive) selection pressures in a competition process, where negative selection of phenotypic 
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subsets may have the same outcome as positive selection of remaining subsets (275) (as is the case 
with residue toggling), the changes in VL allowed us to measure changes in population sizes and, 
thus, selection pressure. Here, the constant WT population size up to six months post infection 
(and between 10 and 20 weeks post the detection of nAbs) suggests there was little/no negative 
(purifying) selection pressure against the WT residue. This contrasts with studies by Bar et al. and 
Moore et al., which both observed significant decreases in the number of WT copies (a two-log 
decrease in the study by Bar et al. using 454 pyrosequencing; while a one log decrease was 
observed in the study by Moore et al. using single genome sequencing) by six months post 
infection (164, 241).  
The WT viruses may persist following nAb responses through several mechanisms. Firstly, the 
high VL in early infection may result in saturation of the nAb response, where the limited nAbs 
produced in the early stages of infection may simply have been insufficient to neutralize all viral 
particles at the given VLs. Several non-human primate (NHP) passive immunization studies have 
shown that high levels of nAbs are required for sterile protection from high dose challenges (±25 
mg/kg) (276–278). If the persistence of nAb sensitive viruses is attributable to saturation of nAbs 
by high VLs, the implications for vaccine development are more favourable, as exposure events 
in natural human transmission involve substantially lower VLs than those used in a high dose NHP 
model (5 x 105 – 2 x 107 copies per ejaculate (279, 280), in comparison to ~ 108 viral copies in a 
typical high-dose challenge experiment, as reported in (202)) or established acute HIV-1 infection. 
This is supported by Hessell et al., who showed that b12, a bnAb targeting the CD4bs of gp120, 
afforded protection to macaques at relatively low concentrations (1 mg/kg) against a low dose 
SHIV challenge (~30x lower than a typical high dose challenge) (202). 
However, another explanation for the persistence of the WT is cell-cell transmission. Here, we 
found that cell-cell transmission of T/F viruses from four CAPRISA 002 participants was highly 
resistant to autologous sera (244). Given the reduced inhibition by autologous plasma antibodies, 
it is possible that cell-cell transmission allowed WT viruses in these participants to escape nAb 
pressure, which may have allowed nAb sensitive virions to persist despite their sensitivity. In 
addition, the reduced inhibition of free virus-cell and cell-cell transmission of mutant viruses, 
compared with WT viruses, may explain the considerable increase in the mutant population 
observed after the detection of nAbs. If the persistence of nAb sensitive viruses is due to cell-cell 
transmission, then these results highlight the importance of antibody effector functions such as 
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ADCC, which can target infected cells. This is supported by two recent non-human primate passive 
immunization studies by Hessell et al. and Liu et al., which showed bnAb-mediated protection 
was partially facilitated by clearing HIV-1 infection in distal tissues (281, 282). 
Determining HIV-1 population dynamics provides important information to understand viral 
variants that may elicit bnAb responses. The limited impact of early nAbs on the overall WT viral 
population size suggests HIV-1 can escape nAbs via mechanisms distinct from mutations and 
insertion/deletions. Here, we demonstrate one mechanism (cell-cell transmission) by which WT 
viruses escape nAbs indirectly, notably allowing nAb sensitive viral variants to persist in the 
presence of autologous nAbs. Consequently, this study highlights the importance of a vaccine 
which elicits nAbs that mediate Fc-effector functions against infected cells to reduce cell-cell 
transmission.   
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ABSTRACT 
Numerous studies, including the RV144 trial, suggest ADCC responses may play a role in a 
protective vaccine. However, there is limited evidence of viral evolution driven by ADCC 
pressure, which would provide strong support for their importance as an immune response. This 
study investigated the relationship between epitopes targeted by nAb and ADCC responses, and 
looked for evidence of ADCC immune escape. 
To identify sites under immune pressure, longitudinal gp160 sequences, and partial gp160 deep 
sequence data covering the region of the nAb epitope, were generated and select mutations were 
introduced into the respective acute/early env. Infectious molecular clones encoding these env 
(Env-IMC) were subsequently used in Luciferase-based ADCC and TZM-bl nAb assays to 
determine the effect of each mutation on both responses. 
In the CAP45 acute Env-IMC, a D462G mutation (in V5) conferred complete escape from both 
neutralizing and ADCC antibodies. In CAP210, two mutations (A161V in V2; V208I in C2) were 
evaluated. A161V had no effect on ADCC activity, but conferred complete resistance to nAbs, 
while V208I conferred complete resistance to the ADCC response, but only partially escaped 
nAbs. Lastly, in CAP239, three mutations (K97E in C1; L278S in C2; S481N in C5) were 
evaluated. K97E and S481N conferred complete resistance to ADCC responses, but had no effect 
on neutralization; while L278S conferred complete resistance to nAbs but had no effect on ADCC 
responses. Analysis of CAP239 gp160 sequences revealed three distinct escape pathways. Env-
IMCs (n=8) from each of the pathways displayed differential resistance to nAb and ADCC 
responses. All Env-IMCs which incorporated S481N were resistant to ADCC, while several escape 
mutations were associated with nAb escape.  
This study provided definitive evidence of ADCC driven immune escape and viral evolution in 
early infection for the first time, supporting previous studies which suggest these responses play a 
role in controlling infection, and highlighting their importance as a vaccine target.  
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3.1 Introduction 
In the RV144 trial, the only vaccine to offer any protection thus far, protection against HIV-1 
infection was associated with V2-directed non-neutralizing antibodies (nnAbs) with Fc-mediated 
effector function (31%) (8). This has raised important questions about the role of antibody effector 
functions, other than neutralization, in protection from HIV-1. Indeed, a number of studies have 
suggested that ADCC responses may be protective against, or control, HIV-1 infection (8, 201, 
212, 283, 284). However, there is limited information on how these responses impact the evolution 
of viral populations in vivo, which would be an important indicator of the pressure these responses 
are able to exert on the virus.   
Escape from nAbs in the HIV-1 Envelope (Env) has been well characterized and is observed 
throughout infection (159, 164). Consequently, any putative pressure exerted by effector functions 
after neutralization is detectable is difficult to deconvolute from neutralization-induced escape. As 
a result, only two studies to date have provided evidence of viral escape from ADCC responses. 
Chung et al. demonstrated escape from ADCC responses in chronic HIV-1 infection (233). This 
study identified mutations in the Env C1 region which escaped ADCC responses. However, this 
study used linear peptides, which likely missed ADCC responses targeting conformational epitope. 
In addition, evidence of a sieve effect which may have been due to ADCC-mediating nnAbs was 
detected in the RV144 trial (285). Here, vaccine efficacy against viruses matched to the vaccine 
protein at position 169 (K169) increased to 48%, whereas efficacy against viruses mismatched at 
position 181 (I181X) was 78%, suggesting V2-targeting nnAbs exerted selection pressure. 
One complication in measuring ADCC is the choice of antigen/target used to measure ADCC 
responses. Many assays use peptides, which are non-conformational and are, therefore, likely miss 
the majority of ADCC responses. In comparison, the use of proteins to coat target cells is quite 
different: it is thought using these gp120/140 proteins represent the virus binding to the CD4 
molecule on the cell membrane and, thus, exposing CD4-inducible (CD4i) epitopes only exposed 
during viral entry (286). The use of virus-infected cells, although technically more difficult, is 
thought to more accurately represent epitopes present during both viral entry and budding from 
infected cells (240). 
Here, we used single genome sequencing, and deep sequencing over the region first targeted by 
nAbs, to map sites under selection in the HIV-1 env, from enrolment to after the detection of nAbs 
Chapter 3 – ADCC responses can drive HIV-1 Envelope evolution 
57 
in three participants of the CAPRISA 002 cohort. In two of the three individuals, putative antibody-
mediated immune pressure was detectable prior to the detection of nAbs. We incorporated these 
mutations, or mutations which developed concurrent with the detection of nAbs, into Env-IMCs 
with the cognate early/acute env, to investigate the effect these mutations on autologous ADCC 
and neutralization responses. In one individual, CAP239, which targeted the CD4bs in early 
infection, we found evidence of ADCC-driven immune escape and env evolution. These data 
provide support for the importance of ADCC responses in early HIV-1 infection, and further 
motivates for their use as targets for an effective HIV-1 vaccine. 
3.2 Methods 
3.2.1 Ethics statement 
Ethics approval was obtained as previously detailed in Chapter 2.2.1. 
3.2.2 CAPRISA 002 acute infection cohort participants 
Longitudinal plasma samples were obtained from the CAPRISA 002 acute infection cohort as 
previously detailed in Chapter 2.2.2.  
3.2.3 Cell lines 
TZM-bl cells and HEK293T cells were obtained and cultured as previously detailed in Chapter 
2.2.3. CEM.NKRCCR5 cells kindly were obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID (catalogue number 4376; contributed by Dr. Alexandra Trkola). 
3.2.4 Peripheral blood mononuclear cells 
For the ADCC assays, appropriate PMBCs were found and used as a source of effector cells 
(Appendix A3). PBMCs were obtained from healthy HIV-1 seronegative donors and isolated by 
Ficoll gradient from buffy coats. Immediately after isolation, PBMCs were counted, resuspended 
in 10% DMSO (Sigma), 20% FCS (Biochrom), 70% RPMI (Lonza) and cooled overnight to -80 
ºC at a rate of -1 ºC/h. The next day, PBMCs were moved to liquid nitrogen storage.  
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3.2.5 RT-PCR amplification and sequencing 
HIV-1 RNA was purified from plasma using the Qiagen Viral RNA kit (Qiagen), and reverse 
transcribed to cDNA using Superscript III Reverse Transcriptase (Invitrogen). Single genome 
amplification (SGA) or end-point dilution was carried out on plasma. Amplicons were directly 
sequenced using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit 
(Applied Biosystems) and resolved on an ABI 3100 automated genetic analyzer. The full-length 
env sequences were assembled and edited using Sequencher v.4.0 software (Genecodes). Multiple 
sequence alignments were performed using Clustal X (ver. 1.83) and edited by eye with BioEdit 
(ver. 5.0.9). 
3.2.6 Deep sequencing library preparation and data processing 
Deep sequencing library preparation and data processing was carried out as previously detailed in 
Chapter 2.2.4. 
3.2.7 Cloning gp160 and mutagenesis 
Cloning and mutagenesis were performed as previously described in Chapter 2.2.6. 
3.2.8 Construction of HIV-1 infectious molecular clones and virus preparation 
CAP210 TF, CAP239 TF, CAP255 2.00.5, CAP257 2.00.Luc, CAP210 TF A161V, CAP210 TF 
V208I and CAP239 TF L278S were described in Chapter 2.2.7. In addition, Env-IMC of 
acute/early viruses for CAP8, CAP61, CAP228 and CAP256 were constructed in the Ochsenbauer 
laboratory as previously described (270). Env-IMCs of the remaining CAP239 mutant viruses 
(K97E and S481N), as well as CAP239 Env-IMCs representing CAP239 envs from 13 wpi (13-
5G3, 13-9C6 and 13-9B2) and 19 wpi (19-7E4, 19-7F4, 19-7F2, 19-7B2 and 19-7C2) were 
constructed at UCT (D Mielke). 
Virus preparation was carried out as previously described in Chapter 2.2.7. 
3.2.9 Infection of CEM.NKRCCR5 cell line with HIV-1 Env-IMC 
CEM.NKRCCR5 cells (1 x 10
6) were infected with 1 mL of virus inoculum by spinoculation at 1000 
x g for 2 h at 32 ºC in the presence of DEAE-Dextran (7.5 μg/mL). The cells were subsequently 
resuspended at 0.3 x 106/mL and cultured for 72 h in R10 containing 7.5 μg/mL DEAE-Dextran. 
Following 72 h of infection, infected cells (1 x 105) were washed in PBS, dispensed in 96-well V-
bottom plates, and stained with a vital dye (LIVE/DEAD Fixable Aqua Dead Cell Stain, 
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Invitrogen) to exclude non-viable cells from subsequent analyses. The cells were then washed 
twice with 250 μL per well of washing buffer (WB; PBS + 1% FCS) and incubated with 
Cytofix/Cytoperm (BD Bioscience) for 20 min at 4 ºC. The cells were then washed twice with 200 
μL of 1% Cytoperm washing buffer (BD Biosciences). After the final wash, the anti-p24 antibody 
(clone KC57-RD1; Beckman Coulter) was added to the cells at a final dilution of 1:400 and the 
plates were incubated for 30 min at 4 ºC. The plates were washed twice with WB, and the cells 
were resuspended in 200 μL 1% formaldehyde-PBS. The samples were acquired within 24 h using 
the LSR II flow cytometer (BD Biosciences). A minimum of 10,000 total singlet events was 
acquired for each analysis. Gates were set to include singlet and live events. The appropriate 
compensation beads were used to compensate the spill over signal for the two fluorophores. Data 
analysis was performed using FlowJo 10.2 software (TreeStar). Uninfected CEM.NKRCCR5 and 
the chronically infected A1953 cell lines were used to titer the vital dye and the anti-p24 antibody, 
and were used as negative and positive controls, respectively, for the described staining procedure. 
Downstream assays performed using the IMC-infected target cells were considered reliable if the 
percentage of viable p24+ target cells on assay day was ≥10%. 
3.2.10 Neutralization assay 
Neutralization assays were performed as previously described in Chapter 2.2.6. 
3.2.11 Luciferase-based ADCC assay 
The Luciferase-based ADCC assay was conducted as stated in the Duke University CFAR protocol 
CFAR01-A0005 and described by Pollara et al. (240). The day prior to the ADCC assay, PBMCs 
to be used in the assay were thawed in R10, counted and assessed for viability. PBMCs were 
resuspended in R10 supplemented with IL-15 (10 ng/mL) (Sigma) overnight.  
On the day of the assay, infected CEM.NKRCCR5 cells were counted, assessed for viability 
(viability had to be ≥ 45% to be used in the assay) and the concentration was adjusted to 2 x 105 
viable cells/mL (5 x 103 cells/well). Stimulated PBMCs were then counted, assessed for viability, 
pelleted and resuspended in the infected CEM.NKRCCR5 cells at a concentration of 6 x 10
6 
PBMCs/mL (1.5 x 105 PBMCs/well) (effector: target cell ratio of 30:1). Plasma, mAbs or controls 
were serially diluted 1:5 starting at 1:50 dilution. The effector/target cell mix and antibody 
dilutions were plated in white opaque 96-well half-area plates (Costar), centrifuged at 300 x g for 
1 min after 30 min, and then incubated for 5.5 h at 37 ºC, 5.5% CO2. After 5.5 h, ViviRen substrate 
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(Promega) was diluted 1:500 in R10 and added 1:1 to the assay wells. The final readout was the 
luminescence intensity generated by the presence of residual intact target cells that have not been 
lysed by the effector population in the presence of ADCC-mediating antibodies. The percentage 
of specific killing was calculated using the formula  
% specific killing = 
RLU of target + effector well - RLU of test well
RLU of target + effector well
 x 100 
 In the analysis, the RLU of the target + effector wells represent spontaneous lysis in the absence 
of any source of antibody. The RSV-specific mAb, Palivizumab (MedImmune) was used as a 
negative control and IgG from individuals chronically infected with HIV-1 (HIVIG) (obtained 
through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Catalogue #3957, from 
NABI and NHLBI) was used as a positive control. All anti-HIV-1 mAbs used in the ADCC assays 
had identical Fc regions with decreased fucosylation for optimized recognition of FcγRIIIa, 
resulting in improved NK cell binding and ADCC (287, 288), and were kindly provided by Dr 
Guido Ferrari (Duke University). All experiments were repeated two to three times. The titer was 
calculated as the lowest mean concentration/dilution which resulted in ADCC above background 
activity. 
3.2.12 Structural modelling and glycosylation changes 
Crystal structures of the HIV-1 Env trimer and gp41 (PDB IDs: 4NCO, 4TVP, and 2B4C) were 
used as templates to create models from the CAP239 gp160 sequences, which was carried out 
using Modeller (289) and the UCSF Chimera package (176). Modelling was done in 10 replicates, 
and the best scoring model was chosen for further analysis. Basic mannose glycans were added at 
selected potential N-linked glycosylation sites using GlyProt (290). 
3.3 Results 
3.3.1 ADCC responses are detectable before nAbs 
We previously showed that heterologous ADCC responses to gp120-coated cells were detectable 
in plasma prior to autologous nAb responses (Bandawe, Mielke et al. publication in preparation). 
In this study, we used early/acute Env-IMCs from nine participants of the CAPRISA 002 acute 
infection cohort (Appendix A2). In all nine participants, ADCC responses were detectable at the 
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time of enrolment (between 3 and 8 wpi), while nAbs became detectable later (between 9 and 22 
wpi) (Figure 3.1 and 3.2).  
Figure 3.1 Kinetics of autologous ADCC and neutralizing antibody development. Early/Acute 
Env-IMCs from nine participants were used to determine kinetics of development of plasma ADCC (red 
lines) and nAb (blue lines) responses over the first six months of infection in nine individuals of the 
CAPRISA 002 acute infection cohort.  
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Figure 3.2 Summary of the time of first detection of ADCC and neutralizing antibody responses. 
The first time-point that ADCC responses (red diamonds) and nAbs (blue circles) in nine individuals of the 
CAPRISA 002 acute infection cohort.  
In seven of the nine participants, ADCC and nAb responses to the early virus increased at 
approximately the same rate after nAbs were detected (Figure 3.1). However, a different pattern 
was observed in two participants, CAP45 and CAP255. ADCC responses in CAP45 followed a 
similar trajectory to nAb development until 14 wpi, after which ADCC responses decrease while 
nAb responses continue to increase. In CAP255, high ADCC titers (>1,000) were observed at 
enrolment (8 wpi), but these decreased considerably by 13 wpi (<150), the next time point tested, 
after which ADCC responses remained low.  
3.3.2 Varied relationship between ADCC and nAb epitopes in early infection 
We then investigated epitopes targeted by ADCC and nAb responses and viral escape in three 
participants (CAP45, CAP210 and CAP239) where we had available data on nAb kinetics and 
targets (164).  
CAP45 nAbs targeted the C3V4 region and were detectable by 9 wpi (163, 164), but escape was 
conferred through mutations in the V5 region (164). In comparison, ADCC responses were 
detectable by 5 wpi (Figure 3.1) and have not been mapped. To identify regions under immune 
pressure in CAP45, we used 31 env sequences (previously generated by Dr Melissa-Rose 
Abrahams, UCT) from five time-points over 1 year of infection (Figure 3.3 A): 20 from 2 wpi; 5 
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from 5 wpi; 1 from 7 wpi; 3 from 12 wpi; 2 from 65 wpi. Due to very low viral loads, only three 
sequences were generated from 12 wpi, around the time of nAb detection, with no amplification 
from the 9 wpi plasma.  
Sequences from 2-7 wpi were highly homogenous, with stochastic mutations consistent with 
Reverse Transcriptase error. However, at 12 wpi a three-residue deletion in the V5 (HxB2 
positions 460-462, 460Δ3) was identified, and by 65 wpi, the viruses harbouring the deletion had 
disappeared, having been replaced by viruses with two mutations in the V5: K460E and D462G. 
To explore viral evolution in the V5 in greater detail, we generated deep sequencing from five 
time-points (enrolment to 14 wpi). A mean of 131 consensus sequences were generated, with a 
range of 52-203 consensus sequences (Figure 3.3 B). We observed the 3-residue deletion (10% of 
the viral population) at 9 wpi, the time of nAb detection, which increased to 23% at 10 wpi and 
60% by 12 wpi, after which it decreased to 45% at 14 wpi. In addition, D462G was detected at 
very low levels (1.5%) at 10 wpi and increased to 11% at 12 wpi and 49% at 14 wpi. To determine 
the impact of these mutations on ADCC and nAb responses, we incorporated the three-residue 
deletion and D462G the acute CAP45 Env-IMC (CAP45 2.00). While the Env-IMC containing 
the deletion was not able to infect target cells at a level sufficient for the ADCC assay, the D462G 
virus (CAP45 2.00 D462G) conferred resistance to both ADCC (Figure 3.3 C) and nAb (Figure 
3.3 D) responses.  
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Figure 3.3 Viral evolution and development of antibody responses in CAP45. 31 single genome 
sequences were obtained from five time-points over 1 year of infection (nAb detection indicated with grey 
shading) (A). Mutations were identified in a segment of the V5 (red box). Relative frequencies of sites 
under selection in the region were measured from deep sequencing data (nAb detection indicated with grey 
shading) (B). One mutation, D462G was introduced into the acute virus, and ADCC (C) and neutralization 
(D) assays were performed to determine the effect of the mutation on each response.
In the second participant, CAP210, nAbs were detected by 16 wpi, while ADCC responses were 
detected at 5 wpi (Figure 3.1). We generated 39 env sequences (14 sequences for this thesis and 
25 kindly provided by Dr Melissa-Rose Abrahams), from six time-points over six months of 
infection to investigate viral evolution (Figure 3.4 A): 12 from 2 wpi; 6 from 5 wpi; 7 from 10 
wpi; 3 from 16 wpi; 4 from 18 wpi; and 8 from 22 wpi.  
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NAb responses were previously mapped to the V1V2 region (164). Here, we identified four 
regions under putative pressure, namely A161V in the V2, V208I in the C2, a six-residue deletion 
in the V4 and several sites in the cytoplasmic domain of gp41. Deep sequencing of the C1C2 
region revealed that both A161V and V208I were detected several weeks before nAbs emerged 
(A161V was present in 10% of variants at 12 wpi, while V208I was present in 15% of variants at 
12 wpi) (Figure 3.4 B). A161V became dominant, concurrent with the detection of nAbs, being 
present in ~ 80% of the viral population, while V208I remained a minor variant (present in 10-
20% of the viral population from 16-26 wpi). 
Both mutations were incorporated into the CAP210 T/F Env-IMC, and their effect on ADCC and 
nAb responses was investigated. CAP210 TF A161V did not have any effect on ADCC responses 
compared to CAP210 TF (Figure 3.4 C), but resulted in resistance to neutralization (Figure 3.4 D). 
In comparison, CAP210 TF V208I was completely resistant to ADCC responses, but only partially 
resistant to nAbs.  
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Figure 3.4 Viral evolution and development of antibody responses in CAP210. 39 single genome 
sequences were obtained from six time-points over six months of infection (nAbs detection indicated with 
grey shading) (A). Mutations were identified in the V2 and beginning of the C2 (red boxes), as well as in 
the V4 and gp41. Relative frequencies of sites under selection in the V2 and C2 were measured from deep 
sequencing data (nAb detection indicated with grey shading) (B). Two mutations, A161V and V208I, were 
introduced into the CAP210 T/F Env-IMC, and ADCC (C) and neutralization (D) assays were performed 
to determine the effect of both mutations on each response.  
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3.3.3 ADCC responses can drive immune escape in early HIV-1 infection 
The last participant, CAP239, developed nAbs targeting the CD4bs, detectable by 13 wpi. In 
comparison, ADCC responses were detectable by 5 wpi (Figure 3.1). To investigate sites under 
selection, we compared 61 gp160 sequences (43 sequences generated as part of this thesis and 18 
sequences kindly provided by Drs Melissa-Rose Abrahams and Florette Treurnicht) from ten time-
points (2-37 wpi).  Two sites were observed under putative immune pressure prior to the detection 
of nAbs, namely K97E and S481N. K97E was detected at in 3/22 sequences generated between 5 
and 11 wpi, after which it was not detected (Figure 3.5 A), while S481N was detected in 2/22 
sequences generated between 5 and 11 wpi, and then in 16/40 sequences generated between 13 
and 37 wpi. Analysis of the prevalence of amino acids at position 481 using AnalyzeAlign 
(https://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze_align.html) showed 
N481 was a rare mutation in subtype C sequences (present in 6.41% of sequences (85/1326)), 
while S481 was the dominant residue at this site (93.29% of sequences (1237/1326)). At the time 
nAbs were detected, two additional sites appeared under immune pressure (a three-residue deletion 
from position 405 to 407, and position 463). From 19 wpi, toggling was observed at four additional 
sites (106, 278, 456 and 463.02).  
To investigate the source of immune pressure, three of these mutations (K97E, S481N and L278S, 
which introduced a PNGS at N276) were incorporated into the CAP239 T/F Env-IMC. K97E and 
S481N were introduced as putative ADCC escape sites, while L278S was introduced as a 
representative nAb escape mutation. While ADCC responses were detected to CAP239 T/F from 
the first time-point, the introduction of K97E resulted in complete resistance to ADCC responses 
until 10 wpi, after which antibodies which recognized the mutant were detected (Figure 3.5 B). 
Similarly, the introduction of S481N was associated with escape from ADCC responses until 22 
wpi, at which time it became sensitive to ADCC responses. Both mutations had no effect on 
neutralization (Figure 3.5 C). The introduction of an L278S mutation resulted in complete 
resistance to nAbs until 15 wpi, after which it was still partially resistant to neutralization up to 22 
wpi (Figure 3.5 C). Interestingly, introduction of an L278S mutation resulted in increased 
sensitivity to ADCC responses in comparison to the T/F Env virus from the first time-point (Figure 
3.5 B), but sensitivity reduced to similar levels as the T/F Env virus by 19 wpi (the time at which 
the mutant was detectable by single genome sequencing).  
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Figure 3.5 Viral evolution and development of antibody responses in CAP239. 62 single genome 
sequences were obtained from ten time-points over nine months of infection (nAb detection indicated with 
grey shading) (A). Mutations were identified across the gp120 in regions in, or proximal to, the CD4bs (red 
boxes). Two mutations detected prior to nAb responses, K97E (green star) and S481N (orange star), as well 
as one mutation observed after the detection of nAbs (L278S; red star) were introduced into the T/F Env-
IMC, and ADCC (C) and neutralization (D) assays were performed to determine the effect of each mutation 
on both responses.  
3.3.4 ADCC and nAb responses drive viral evolution along distinct pathways 
These results suggest that ADCC responses exerted pressure on the virus resulting in escape and 
that early ADCC and nAb responses targeted different epitopes. We were thus interested in how 
ADCC and nAb responses differentially impacted Env evolution. A maximum-likelihood 
phylogenetic tree of CAP239 Env sequences revealed three distinct pathways that emerged before, 
or at the time of, nAb detection (Figure 3.6). Pathway one (blue) was the earliest response 
(detectable from 5 wpi) and was characterised by escape in the C4C5 region (S481N and 
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E463K/G). This pathway was a dead-end evolutionary pathway as it was not detected after 22 
weeks. The second pathway (purple) was characterized by mutations in loop D (L289S), the C5 
(S481N) as well as deletions and toggling in the V5 (at positions 462 – 463.02) while pathway 
three (red) was observed from 19 wpi, and was characterized by mutations in the C1 (K106E), 
loop D (L278S) and C4V5 (W456R and K463.02E) regions.  
To investigate how viral evolution in each of these pathways affected sensitivity to ADCC and 
nAb responses, we constructed Env-IMCs which incorporated the T/F env (black) or eight envs 
detected at 13 or 19 wpi (Figure 3.6) (list of mutations from the CAP239 T/F env are listed in 
appendix A2). Of the five Env-IMCs from pathway one, all five were resistant to ADCC (Figure 
3.7 A,C) from contemporaneous plasma, while four of the five Env-IMCs were sensitive to 
contemporaneous nAbs (Figure 3.7 B,D). All three 13-week Env-IMCs were resistant to 
contemporaneous ADCC responses but sensitive to nAbs (Figure 3.6 C,D). Of the two 19-week 
Env-IMCs from pathway one, both Env-IMCs were completely resistant to contemporaneous 
ADCC responses, while one Env-IMC (CAP239 19-7F4) was 8-10 times more sensitive than the 
T/F Env-IMC to nAbs present at 19wpi, and the other Env (CAP239 19-7B2) was resistant to these 
nAb responses. The Env-IMC from pathway two (CAP239 19-7C2) was resistant to both ADCC 
and nAb responses present at 19 wpi. Finally, the two Env-IMCs from pathway three (CAP239 
19-7E4 and CAP239 19-7F2) were as sensitive to contemporaneous ADCC responses as the T/F
Env-IMC, but were resistant to nAbs. 
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Figure 3.6 Evolution along multiple pathways in CD4bs regions of CAP239 viruses. A maximum-likelihood tree of the 62 CAP239 gp160 
single genome sequences was constructed, and rooted on the T/F virus. Branches were colour-coded according to the time-point from which the 
sequence was sampled. Three distinct evolutionary pathways were observed at the time of, or just after, detection of nAbs. The first pathway was 
typified by an S481N mutation in the C5 (blue box); the second pathway was characterized by an L278S mutation in loop D, as well as S481N and 
a combination of deletions and toggling in the V5 (purple box); and the last pathway was characterized by K106E in the C1, L278S in loop D, as 
well as W456R and K464E in the V5 (red box). Env-IMCs of the T/F as well as eight representative sequences from the three pathways were 
constructed (identified by stars and the clone name). Three of the clones (CAP239 13-5G3, CAP239 13-9C6 and CAP239 13-9B2) represented 13 
week viruses; while five viruses (CAP239 19-7F4, CAP239 19-7B2, CAP239 19-7C2, CAP239 19-7F2 and CAP239 19-7E4) represented 19 week 
viruses.
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Figure 3.7 Impact of evolutionary pathways on recognition by ADCC and neutralization 
responses. ADCC responses against, (A) and neutralization of (B), the CAP239 TF and eight viruses from 
13 and 19 weeks post infection. The fold difference in sensitivity between each virus and CAP239 TF at 
the time point from which each virus was isolated and sequenced to ADCC (C) and neutralization (D) was 
then calculated. 
The CAP239 T/F Env trimer, as well as representative Envs from each pathway, were then 
modelled onto the most representative trimer structure available, and one gp120 subunit was used 
to identify putative changes in the gp120 structure (Figure 3.8). Models of all pathways exhibited 
structural or charge changes in the V5: in pathway one, E462G resulted in a small helix in the V5; 
in pathway two, the V4 and V5 became less structured (including the loss of a β sheet in the V4), 
possibly due to a three-residue deletion in the V5; pathway three introduced a charge reversal in 
the V5 (K463.02E). In addition, a glycan was added at N276 in pathways two and three, which 
may have shielded the antibody epitope. Pathway three also introduced W456R in the β23 sheet, 
and a charge change (K106E) in the C1.  
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Of interest, S481N, which escaped ADCC responses and was observed in pathways one and two 
(resistant to ADCC), was buried within the gp120 (Figure 3.8 A, black shading).  
Figure 3.8 Models of the CAP239 TF gp120 and representative gp120s from each evolutionary 
pathway. Gp120 models of CAP239 TF and Envs from each of the three evolutionary pathways were 
constructed using Modeller (289) and the best scoring model was visualised using Chimera (176). Basic 
glycans were added at N276 in pathway two and three, which incorporated the glycan, using GlyProt (290). 
Structural landmarks (grey) and key residues in CAP239 viral evolution (black) are shown on CAP239 TF 
gp120 (A). Changes characteristic to each evolutionary pathway are shown in blue (CAP239 19-7F4; 
pathway one) (B), purple (CAP239 19-7C2; pathway two) (C) and red shading (CAP239 19-7H2; pathway 
three) (D). 
3.3.5 Differential neutralization and ADCC profiles of CAP239 TF by anti-HIV-1 
monoclonal antibodies 
The inaccessibility of S481 (ADCC sensitive), predicted by the modelling, suggested the Env 
structure on free virions and on the surface of infected cells may be different. To test this, we used 
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six bnAbs targeting diverse regions of the Env (Appendix A5) and with Fc regions optimized to 
bind FcγRIIIa (kindly provided by Dr Guido Ferrari, Duke University) to determine neutralization 
of the CAP239 TF Env virus and ADCC against CAP239 TF-infected cells. Of the six bnAbs we 
used, VRC01 and 3BNC117 (CD4bs bnAbs) were not able to neutralize CAP239 TF up to 10 
μg/mL, while the other four bnAbs neutralized CAP239 TF with varying potency (Figure 3.9). In 
comparison, VRC01 and 3BNC117 could mediate ADCC against CAP239 TF-infected cells, 
while only PGT151 (which could neutralize CAP239 TF free virions) was not able to mediate 
ADCC against CAP239 TF-infected cells up to 10 μg/mL. 
Figure 3.9 Radial plot indicating differential neutralization and ADCC profiles against CAP239 
TF free virions and infected cells using six bnAbs. The neutralization (blue) and ADCC (red) profile 
against CAP239 TF are shown on a radial plot, with each spoke representing a bnAb. Sensitivity to each 
bnAb is indicated by the distance of the point between the centre (resistant) and circumference (sensitive). 
3.4 Discussion 
This study provided evidence of ADCC-mediated immune pressure in early infection for the first 
time. We found, similar to other studies (146, 189, 291), that autologous ADCC responses in nine 
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tracked the impact of early ADCC and nAb responses on viral env evolution in three individuals. 
In one individual, we identified two mutations which appeared almost two months prior to the 
detection of nAbs and distinct from the apparent nAb epitope. Both mutations had no effect on 
neutralization, but resulted in resistance to ADCC responses. Longitudinal env sequencing of 
plasma variants revealed three evolutionary pathways, which developed from infection until nine 
months post infection, two of which included one of the ADCC escape mutations and were 
resistant to ADCC responses. This suggests ADCC responses can directly impact viral evolution 
in vivo. 
Many nAbs can mediate ADCC (reviewed by Pollara et al. (228)), indicating several Env epitopes 
are present on both free virions and on the surface of infected cells. Here, a nAb escape mutation 
in the V5 (D462G) of viruses in one participant (CAP45) resulted in resistance to ADCC, 
suggesting these responses overlapped or were mediated through the same antibody. However, 
this pattern was not observed in CAP210 where two mutations had distinctly different effects on 
neutralization and ADCC: one escape mutation (A161V) resulted in resistance to nAbs but had 
not effect on ADCC, while the other mutation (V208I) resulted in resistance to ADCC responses 
but had a limited effect on neutralization. This could suggest neutralization and ADCC were 
mediated via different antibodies, or the same antibody bound different forms of the epitope on 
the Env of free virions and on the surface of infected cells. The latter is possible because the 
relationship of Env epitopes on free virions and infected cells is likely complex and there is 
evidence that not all Env epitopes accessible on the surface of infected cells are present on the 
native trimer (100). This is further supported by the differential neutralization and ADCC profiles 
of bnAbs against CAP239 TF free virions and infected cells, respectively.  
Several studies have suggested ADCC responses may play an important role in an effective HIV-
1 vaccine, including the RV144 trial (8). However, only one other study to date has provided 
evidence of escape (which may provide a measure of the importance of an immune response) from 
ADCC responses in chronic infection (233). In that study, Chung et al. identified escape from 
ADCC responses mapped to the C1 region. Furthermore, several other studies have identified this 
region as a common target of ADCC-mediating antibodies (191, 229). Here, we identified one site 
in the C1 (K97E) of CAP239 viruses under weak selection pressure in early infection which 
facilitated resistance to ADCC responses but had no effect on neutralization, suggesting this region 
was also targeted by nnAbs in our study.  
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In addition, numerous ADCC-mediating nnAbs have been mapped to the C5, usually close to the 
gp120 C terminus (203, 226, 292). We identified ADCC escape at a single site in the C5 region 
(S481N) of CAP239 viruses, anterior to the epitopes previously characterized, which appeared 
inaccessible to antibodies in the closed trimer model. This mutation did not have any effect on 
neutralization, but induced resistance to ADCC. In addition, the mutation was fixed in two of the 
three viral evolutionary pathways identified, suggesting there was immune pressure on this site. 
Viruses from the first pathway were detected in sequences from 6 wpi (seven weeks prior to the 
detection of nAbs) and continued until 22 wpi, after which it was not detected. Earlier sequences 
only contained the ADCC escape mutation, but later viruses incorporated nAb escape mutations 
in the V5 as well, suggesting there was a dynamic adaptation process to pressure from both 
responses.  
The two remaining pathways were observed after the detection of nAbs (from 19 wpi). Pathway 
two, which contained the exclusive ADCC escape mutation, was present through to 37 wpi (the 
last time-point sequenced) suggesting ADCC pressure continued to play a role in driving viral 
evolution up to this time-point. However, the third pathway incorporated mutations distinct from 
the first two pathways and was not resistant to ADCC responses. The continuation of this pathway, 
despite sensitivity to ADCC responses, suggests ADCC pressure on the viral Env was relatively 
weak compared to nAb pressure. 
The presence of variants sensitive to contemporaneous nAbs was unexpected, but has been 
observed and reported previously (164, 293). In this study, while both clones which exhibited 
heightened sensitivity to nAbs (CAP239 13-5G3 and CAP239 19-7F4) were also resistant to 
ADCC responses, it does not seem likely that ADCC pressure resulted in nAb sensitive variants, 
as other ADCC resistant variants with similar escape mutations were not nAb sensitive. Instead, 
both variants contained transient mutations outside of the apparent epitope which may have 
resulted in increased neutralization sensitivity. CAP239 19-7F4 incorporated a glycan at N234 
(A236T), which has been reported to alter susceptibility to neutralization by CD4bs antibodies 
(294) and may have done so here; while G600E, which added a charged side chain at a highly
conserved site close to the gp41 fusion domain, was present in CAP239 13-5G3 and may have 
resulted in increased susceptibility to neutralization. 
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In summary, the ability to force immune pressure provides an indication of the importance of an 
immune response. We demonstrate ADCC driven immune escape and viral evolution in early 
infection for the first time, showing that these responses can exert selective pressure on HIV-1. 
Here, viruses that were ADCC resistant were selected for in the absence of nAb pressure. However, 
after nAbs developed the virus evolved to preferentially escape these responses, often without 
escaping ADCC, indicating nAbs exert stronger selective pressure on the virus. These data suggest 
that while eliciting nAbs should be the primary goal of HIV-1 vaccine design, ADCC-mediating 
antibodies may also play an important role in a protective vaccine. 
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Chapter 4. CD4i non-neutralizing antibodies display the greatest 
ADCC breadth and potency against subtype C viruses 
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ABSTRACT 
A better understanding of the relationship between neutralization and ADCC activity of antibodies 
is important to guide the development of immunotherapies and antibody-based vaccines for the 
treatment or prevention of HIV-1 infection. Here, we assessed ADCC breadth of broadly 
neutralizing antibodies (bnAbs) and non-neutralizing Abs (nnAbs) against a panel of subtype C 
viruses.  
Seven bnAbs (VRC01, 3BNC117, PG9, 697D, PGT151, 2G12 and 10E8) and four nnAbs (C11, 
A32, CH58 and HG107) were evaluated for ADCC activity against a panel of nine viruses with 
early/acute subtype C Envelopes. We found bnAb ADCC breadth ranged from 11-66%, while 
nnAb ADCC breadth ranged from 33-100%, of which the two CD4-induced (CD4i) nnAbs (A32 
and C11) were the broadest and most potent antibodies against our virus panel. Further, our data 
showed anti-HIV-1 monoclonal antibodies (mAbs) which had the highest binding capacity to 
infected cells generally exerted the most potent ADCC responses (rs = -0.5309, p = 0.0001).  
Epitopes on free virions are likely to differ from those on the surface of infected cells. However, 
some bnAbs still mediated broad ADCC activity, suggesting there are some common epitopes on 
free virions and the surface of infected cells. The nnAbs targeting the CD4i cluster A epitopes 
displayed the most potent and broad ADCC activity, suggesting these antibodies may be more 
relevant for interventions that aim to eliminate virus infected cells.   
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4.1 Introduction 
An HIV-1 vaccine which elicits bnAbs is a goal of the HIV vaccine field. Recently many highly 
potent bnAbs have been isolated and characterised, and numerous studies have shown they can 
protect from viral acquisition or can slow disease progression in humanized mouse and non-human 
primate studies (295–300). In addition, three clinical trials, which administered individual bnAbs 
(VRC01, 3BNC117 and 10-1074) to viremic patients, displayed a viral load reduction of up to 2.5 
logs, providing definitive evidence of the clinical benefit of anti-HIV bnAbs in humans for the 
first time (301–303).  
Many bnAbs, targeting diverse regions of the Env (including the CD4bs, V1V2 and V3 loops, and 
MPER), can mediate ADCC (304–307). In addition, the Fc region of bnAbs has consistently 
played an important role in therapeutic efficacy against SHIV and HIV-1 (201, 308, 309). 
Recently, the kinetics of HIV-1 suppression in infected individuals with passively administered 
3BCN117 suggested Fc-mediated effector functions played a role by clearing infected cells (310). 
This is corroborated by two recent non-human primate studies by Hessell et al. and Liu et al., 
which showed bnAb-mediated protection was partially facilitated by clearing HIV-1 infection in 
distal tissues (281, 282). 
The RV144 trial raised questions in the field about the potential protectiveness of nnAbs. These 
antibodies target numerous epitopes on the HIV Env (286, 311), which include the gp41 
immunodominant domain, corresponding to a loop typically hidden under the gp120 trimer on 
mature virions (312) and different conformational CD4-induced (CD4i) epitopes revealed after 
Env binding to CD4 (286, 311, 313, 314). The classical examples of CD4i nnAbs are A32, which 
targets the C1, and 17B, which targets the co-receptor binding site (229).  
HIV-1 subtype C accounts for almost half of the global epidemic (29), and consequently is a major 
focus of vaccine efforts. Here, we assessed ADCC breadth using eleven anti-HIV-1 mAbs, 
including seven bnAbs and four nnAbs, and a panel of nine viruses with acute/early subtype C 
envelopes. We found bnAbs had low to moderate ADCC breadth against subtype C viruses. 
However, the classical CD4i nnAbs, A32 and C11, exhibited broad and potent ADCC. We then 
explored the relationship between ADCC activity and binding to the surface of infected cells using 
the same eleven mAbs. Our data showed mAbs which bound infected cells the strongest generally 
mediated the most potent ADCC responses.  
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4.2 Methods 
4.2.1 Ethics statement 
Ethics approval was obtained as detailed in Chapter 2.2.1. 
4.2.2 Cell lines 
TZM-bl cells and HEK293T cells were obtained and cultured as previously detailed in Chapter 
2.2.3. CEM.NKRCCR5 cells were obtained and cultured as described in Chapter 3.2.3. 
4.2.3 Peripheral blood mononuclear cells 
PBMCs were obtained and maintained as previously described in Chapter 3.2.4. 
4.2.4 Construction of HIV-1 infectious molecular clones and virus preparation 
Env-IMCs were constructed as described in Chapter 3.2.8 and virus preparation was carried out as 
described in Chapter 2.2.7. 
4.2.5 Infection of CEM.NKRCCR5 cells with HIV-1 IMCs 
CEM.NKRCCR5 cell infection was carried out as previously described in Chapter 3.2.9. 
4.2.6 Luciferase-based ADCC assay 
The Luciferase-based ADCC assay was performed as previously described in Chapter 3.2.12. All 
anti-HIV-1 mAbs used in the ADCC assays had identical Fc regions with decreased fucosylation 
for optimized recognition of FcγRIIIa, resulting in improved NK cell binding and ADCC (287, 
288), and were kindly provided by Dr Guido Ferrari (Duke University). 
4.2.7 Indirect cell-surface staining 
Infected CEM.NKRCCR5 cells were obtained as previously described (Chapter 3.2.5). Cells 
incubated in the absence of virus (mock infected) were used as a negative infection control. 
Following infection, infected and mock infected cells (2 x 105/well) were washed in PBS, 
dispensed into 96-well V-bottom plates and incubated with 5 μg/mL mAb for 2 h at 37 ºC. 
Subsequently, cells were washed twice with 250 μL/well of WB and stained with vital dye 
(Live/Dead Fixable Aqua Dead Cell Stain, Invitrogen) to exclude nonviable cells from subsequent 
analysis. Cells were then washed with WB, resuspended in 100 μL/well Cytofix/Cytoperm (BD 
Biosciences) and incubated in the dark for 20 min at 4 ºC. Following the incubation period, cells 
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were washed in 1% Cytoperm wash solution (BD Biosciences) and co-incubated with anti-p24 
antibody (clone KC57-RD1; Beckman Coulter) to a final dilution of 1:400 and a secondary FITC-
conjugated antibody (goat anti-human IgG(H+L)-FITC, 172-1006; KPL) to a final dilution of 
1:100, and the plates were incubated in the dark for 25 min at 4 ºC. Cells were washed three times 
with 1% Cytoperm wash solution (BD Biosciences) and resuspended in 150 μL PBS-1% 
paraformaldehyde. The samples were acquired within 24 h using an LSR II flow cytometer (BD 
Biosciences). A minimum of 10,000 total events was acquired for each analysis. Gates were set to 
include singlet and live events. The appropriate compensation beads were used to compensate the 
spill over signal for the three fluorophores. Data analysis was performed using FlowJo 10.2 
software (TreeStar). The median fluorescent intensity (MFI) of surface binding for each anti-HIV-
1 antibody was calculated by first subtracting the background florescence, calculated as the MFI 
of virus-infected cells stained with the secondary antibody in the absence of anti-HIV-1 antibodies, 
and then subtracting the MFI for each anti-HIV-1 mAb stained on the surface of mock (uninfected) 
cells. 
4.2.8 Sequence alignment and analysis 
Multiple sequence alignments were performed using Mega (v7.0.21) (315) and edited by eye with 
BioEdit (ver. 5.0.9) (264). Maximum-likelihood trees were generated using FastTree (v2.1) (316) 
and visualized using FigTree (v1.4.3). 
4.2.9 Statistical and graphical analysis 
Statistical analysis and generation of graphs were completed using Prism (v6.01) (Graphpad). 
4.3 Results 
4.3.1 The subtype C Env-IMC panel is broadly representative of acute subtype C 
envelopes 
To explore the breadth of anti-HIV-1 antibody responses against subtype C viruses, we used a 
panel Env-IMCs (n=11) with HIV-1 subtype C acute/early envs constructed by the Ochsenbauer 
group (UAB) (n=10), and Williamson group (D Mielke, UCT) (n=1) (described in Appendix A2). 
To determine if  this panel represented acute subtype C envs, we compared the panel viruses to 69 
acute subtype C env sequences generated by Abrahams et al. (104) (Figure 4.1). Envs from the 
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panel (shown in blue) were distributed evenly around the tree, indicating that this panel was 
broadly representative of acute subtype C sequences.  
Figure 4.1 Maximum-likelihood phylogenetic tree illustrating the representativeness of the 
acute/early subtype C Env-IMC panel. The ectodomain of Env-IMC env sequences were aligned with 
the ectodomain of envs from the dataset, as all Env-IMCs contained the rev response element and 
endodomain of NL4-3. A maximum-likelihood tree was then constructed and ENV-IMC envs (represented 
by blue labels) were visualized in an unrooted tree of 69 acute subtype C env sequences (104). Scale bar = 
0.03 substitutions per site. 
4.3.2 CD4i non-neutralizing antibodies display the greatest ADCC breadth and 
potency against subtype C viruses 
To determine the breadth and potency of ADCC responses against an acute/early subtype C Env-
IMC panel (n=9), we used a selection of eleven anti-HIV-1 mAbs, including seven bnAbs targeting 
the CD4bs (VRC01, 3BNC117), V2 (PG9, 697D), V3 glycan (2G12), gp120/41 interface 
(PGT151) and MPER (10E8) and four nnAbs targeting the CD4i epitopes (A32, C11) and V2 
(CH58, HG107) (Appendix A5) (Table 4.1, Figure 4.1). Two Env-IMCs (CAP177 TF and CAP256 
2.00, Appendix A2) were removed from the virus panel as they did not meet the infection criteria 
for the ADCC assay (Appendix A6, Table A6.1). 
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Of the seven bnAbs, the CD4bs bnAbs had the broadest ADCC activity, with VRC01 recognizing 
66% (6/9) of the panel; while 3BNC117 recognized 56% (5/9) (Table 4.1, Figure 4.2). The bnAbs 
recognising the MPER (10E8) and V2 (PG9) had slightly lower ADCC breadth, both recognising 
56% (5/9) of the panel viruses, while the gp120/41 interface antibody (PGT 151) ADCC breadth 
was only 33% (3/9). Lastly 697D (V2) and 2G12 (V3 glycans) had very narrow breadth, only 
recognizing 11% (1/9) of the panel.   
10E8 mediated the most potent ADCC against the panel (defined as the lowest dilution of mAb 
that mediated ADCC activity above background) followed by VRC01, which was over two times 
more potent than 3BNC117 (Table 4.1, Figure 4.2). Of the seven bnAbs, 2G12 and 697D mediated 
ADCC with the lowest potency. 
Of the four nnAbs we tested, the two CD4i nnAbs (C11 and A32) had the greatest ADCC breadth, 
with C11 recognizing 100% (9/9) of the panel and A32 recognizing 78% (7/9) of the panel. In 
contrast, the two V2-targeting nnAbs (CH58 and HG107) exhibited lower breadth (33% (3/9) and 
44% (4/9), respectively). In addition, C11 and A32 were the most potent mAbs (0.14 µg/mL and 
0.06 µg/mL, respectively), with A32 (the most potent nnAb tested) over 13 times more potent than 
10E8, the most potent bnAb tested (Table 4.1, Figure 4.2). As with the breadth, CH58 and HG107 
showed low potency. 










CD4bs 66% (6/9) 1.85 
3BNC117 CD4bs 56% (5/9) 4.09 
PG9 V2 56% (5/9) 3.66 
697D V2 11% (1/9) 5.95 
PGT151 Gp120/41 interface 33% (3/9) 4.48 
2G12 V3 glycans 11% (1/9) 6.64 
10E8 MPER 56% (5/9) 0.81 
C11 
Non-neutralizing 
CD4i 100% (9/9) 0.14 
A32 CD4i 78% (7/9) 0.06 
CH58 V2 33% (3/9) 7.35 
HG107 V2 44% (4/9) 3.64 
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Figure 4.2.  Radial plots representing ADCC breadth and potency profiles of seven bnAbs and 
four nnAbs. Each plot shows the ADCC profile of a bnAb (red)/nnAb (blue) against nine viruses (spokes). 
Antibody ADCC potency increases as the distance from the centre of the plot increases. 
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4.3.3 Viruses exhibit differential susceptibility to ADCC 
To investigate if viruses displayed differential susceptibility to ADCC, as has been shown for 
neutralization sensitivity, we ranked the nine viruses according to the ADCC geometric mean titer 
(GMT) against each virus (Figure 4.3). Of the nine viruses, CAP255 ranked the most resistant to 
ADCC (recognized by five of the eleven mAbs, but with titers <1 μg/mL for all of them) while 
CAP239 was the most sensitive to ADCC mediated by the 11 mAbs, being recognized by eight of 
eleven mAbs at low titers. In general, there seemed to be a hierarchy of resistance/sensitivity to 
ADCC, suggesting there may be some intrinsic Env characteristics that confer 
resistance/sensitivity to ADCC. 
Figure 4.3. Susceptibility of subtype C viruses to ADCC by 11 anti-HIV-1 mAbs. Viruses were 
ranked by susceptibility to ADCC from 11 mAbs (7 bnAbs and 4 nnAbs). BnAbs are shown by red dots 
and nnAbs are shown by blue dots. The geometric mean titer of ADCC against each virus is indicated by 
the black line. 
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4.3.4 The most potent ADCC-mediating mAbs efficiently bind to the surface of 
infected cells 
ADCC effector function requires anti-HIV-1 antibodies to bind to viral antigens on the surface of 
infected cells. To investigate the relationship between ADCC and binding to Env on infected cells, 
we used the same 11 anti-HIV-1 mAbs against the acute/early subtype C env virus panel.  
The median fluorescent intensity (MFI) of a FITC-conjugated secondary antibody which bound to 
IgG antibody was used to quantify anti-HIV-1 antibody binding to infected cells. No linear 
relationship between mAb ADCC titer and surface binding was found when ADCC titers above 
the maximum threshold of 10 μg/mL were included (n=94) (r = 0.1537, p=<0.0001), and did not 
change when data points above the ADCC titer threshold were removed (as these antibodies may 
have still bound to antigen, but only mediated ADCC at higher concentrations tested) (n=46) (r = 
0.1443, p=0.0092).  
Each mAb was then ranked by ADCC GMT against the nine viruses, and the corresponding mean 
MFI for each mAb was calculated (Figure 4.4). NnAbs A32, C11 and bnAb 10E8, which ranked 
the highest by ADCC GMT (0.0603 μg/mL, 0.1463 μg/mL and 0.8132 μg/mL, respectively), also 
bound Env on the surface of infected cells most efficiently (mean MFI = 2516, 1736 and 730). In 
contrast, nnAb CH58, which ranked the lowest by ADCC GMT (7.3570 μg/mL), had the lowest 
binding to the surface of infected cells (mean MFI = 7.25). When testing for a non-linear 
relationship (by rank), the Spearman’s rho indicated there was a non-linear inverse relationship 
between ADCC titer and surface staining MFI (rs = -0.4402, p < 0.0001), which increased when 
data points with ADCC titer ≥ 10 μg/mL were removed (rs = -0.5309, p = 0.0001). 
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Figure 4.4 ADCC activity and surface binding of 11 anti-HIV-1 mAbs. The ADCC titer (red) and 
MFI (blue) were plotted for each mAb against nine viruses. MAbs were ranked by ADCC GMT (red lines) 
and the mean MFI (blue lines) for each mAb was also plotted.  
4.1 Discussion 
There is increasing evidence that FcγR-dependent functions are important for optimal antibody 
anti-HIV-1 activity (201, 202, 308, 309). Consequently, a better understanding of Fc effector 
functions of neutralizing and non-neutralizing antibodies is important to guide the development of 
immunotherapies and antibody-based vaccines for the treatment and prevention of HIV-1 
infection. Here, we explored the breadth of ADCC activity mediated by seven bnAbs and four 
nnAbs targeting diverse regions of the Env against nine early/acute subtype C viruses. In general, 
the breadth of ADCC exerted by bnAbs was low to moderate, with the CD4bs bnAbs (and in 
particular, VRC01) exhibiting the highest breadth against our panel. Instead, the two CD4i nnAbs 
we used (A32 and C11) mediated the broadest and most potent ADCC. In addition, as expected, 
the level of ADCC activity was predicted by the ability of a mAb to bind Env on the surface of 
infected cells. 
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Epitopes on the Env trimer of virions are not necessarily accessible on the surface of infected cells. 
Acharya et al. showed the importance of antibody orientation for Fcγ-receptor interaction, 
highlighting the impact fine differences in the epitope footprint, or angles of approach, may have 
on ADCC activity (317). It is possible this played a role in the levels of ADCC activity exhibited 
by the bnAbs used in this study. In particular, this may explain the profile exhibited by PGT151, 
which binds the gp120-gp41 interface on the Env trimer. This bnAb has a high reported 
neutralization breadth against subtype C viruses (73%) (318), and bound to Env on the surface of 
infected cells with relatively high affinity, yet poorly mediated ADCC. 
In contrast to nAb epitopes, many nnAb epitopes are not accessible on the closed Env trimer. These 
include the targets of A32 and C11, which bind CD4i epitopes of the gp120 inner domain (61, 229, 
319–321). Previously, Bruel et al. reported nnAbs had low ADCC breadth against a panel of eight 
T/F HIV-1 strains (322). However, these nnAbs did not include the prototypic CD4i antibodies 
A32 and C11. In this study, similar to Bruel et al., we found the two V2 nnAbs we used (CH58 
and HG107) were relatively narrow and weak at eliciting ADCC. However, A32 and C11 were 
the most broad and potent mediators of ADCC, in agreement with previous studies (191, 229). 
Furthermore, both nnAbs bound infected cells efficiency. Together, this suggests the A32 and C11 
epitopes are conserved in subtype C viruses. Interestingly, von Bredow et al. reported resistance 
of NL4-3-infected cells to A32-mediated ADCC, possibly due to down-modulation of CD4 on the 
surface of infected cells (305). However, our subtype C Env-IMC panel utilized an NL4-3 
backbone. Consequently, it seems more likely the NL4-3 Env did not contain the A32 epitope.  
Understanding the breadth of ADCC responses by anti-HIV-1 antibodies is important to 
understand if bnAbs elicited by a vaccine will also be able to target infected cells. The breadth of 
ADCC activity mediated by some bnAbs implies there are some common epitopes on free virions 
and the surface of infected cells, suggesting these bnAbs would be able to clear early infected 
tissues. In addition, nnAbs targeting the CD4i epitopes displayed potent and broad ADCC activity, 
suggesting these antibodies may be worth exploring as additional vaccine targets.  
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Chapter 5. Conclusions 
Almost thirty-five years after HIV-1 was discovered, a protective vaccine remains elusive. 
However, many studies have provided valuable insight into what might constitute a protective 
immune response. Passive immunization studies have indicated neutralizing antibodies (nAbs) 
have the potential to provide sterilizing protection. In addition, the RV144 vaccine trial, among 
other studies, indicated antibody Fc effector functions, such as ADCC, may play an important role 
in an effective vaccine. In this study, we wished to understand the impact of both responses on 
early HIV-1 Envelope evolution to further inform vaccine design. 
Recent advances in deep sequencing approaches, coupled with the primer ID method which 
barcodes each viral genome, enabled us to generate thousands of viral sequences over time and 
accurately track viral population dynamics. In three of the seven individuals we investigated, we 
found that the absolute population of nAb sensitive viruses remained relatively stable, despite 
detectable nAbs. The decrease in frequency of this population relative to the escape variant was 
attributable to an outgrowth of the escaped virus which resulted in an increase in the overall viral 
load. For vaccine studies, it will be important to further understand the mechanism by which the 
virus persists despite antibody responses, and if this phenomenon occurs in chronic infection, in 
the presence of a broader antibody response. In addition, we found that early nAbs do not 
effectively inhibit cell-cell transmission, providing further evidence for the significance of 
antibody effector functions such as ADCC in a vaccine, which can target infected cells and 
potentially prevent cell-cell transmission. 
If ADCC responses are important in controlling viral populations, we expected to find evidence of 
viral escape from these responses. In nine participants, we found that ADCC responses emerged 
before nAbs, enabling us to define ADCC-mediated pressure. To explore this, we evaluated three 
participants in detail. In all three participants, we observed limited evolution after ADCC responses 
were detected but prior to nAbs. In contrast, once nAbs developed, there was a marked divergence 
in the nAb epitope. In one individual, nAb and ADCC responses targeted the same epitope, 
suggesting they may have been mediated via the same antibody. However, the relationship 
between these responses in the other two participants was more complex. In one participant, we 
found ADCC-driven immune escape and viral evolution in early infection, providing evidence of 
their importance as an immune response. However, soon after nAbs developed, these viruses 
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evolved to preferentially escape nAbs, often without escaping ADCC, indicating nAbs exerted 
significantly stronger selection pressure on the virus.  
Lastly, several ongoing clinical trials are assessing the protectiveness of broadly neutralizing 
antibodies (bnAbs) by passive immunization, and there is evidence their protective efficacy is 
enhanced by Fc function. Here, we used a panel of anti-HIV-1 mAbs and a panel of viruses with 
early/acute subtype C Envs to explore the ADCC breadth of broadly neutralizing and non-
neutralizing antibodies against infected cells. We found bnAbs had low to moderate (11-66%) 
ADCC breadth. However, their potency was generally low (ranging from 0.81 µg/mL for 10E8 - 
6.64 µg/mL for 2G12). In contrast, while the V2 nnAbs were narrow (33-44%) and not potent 
(3.64-7.35 µg/mL), two of the CD4i nnAbs (A32 and C11) exhibited higher breadth (78-100%) 
and were highly potent (0.06-0.14 µg/mL) (A32 was 13.5 times more potent that the most potent 
bnAb, 10E8). Larger panels of infectious molecular clones need to be constructed, such as those 
developed for characterising nAbs, to fully understand the relationship between neutralization and 
ADCC.  
In conclusion, this study was the first to show a stable persistence of nAb sensitive viruses in early 
natural infection, highlighting the need to further understand how these viruses persist as this poses 
a potential challenge for vaccine responses. In addition, we provide further motivation for 
including antibody effector functions, such as ADCC, in an HIV-1 vaccine. To our knowledge this 
study was the first to provide evidence of ADCC-driven immune escape in early infection, showing 
that these responses can exert selective pressure on HIV-1, albeit less than nAbs. The moderate 
ADCC breadth of some bnAbs indicates there are common epitopes on free virions and on the 
surface of infected cells, and evaluating further anti-HIV-1 antibodies against subtype C viruses 
will provide further information as to which bnAbs/nnAbs or combinations may be suitable for 
prevention and treatment programmes. A vaccine should elicit both bnAb and ADCC responses, 
and ideally bnAbs used in passive immunization strategies should target a common 
neutralization/ADCC epitope, such that it was able to potently neutralize free virions and kill 




Appendix A1. Supplementary figures for chapter two 
Table A1.1. Sequence characteristics of seven CAPRISA 002 participants based on results 
from Poisson-fitter (272). 
Participant Sequence convolution 
CAP45 Follows a star-phylogeny 
CAP63 Follows a star-phylogeny 
CAP88 Follows a star-phylogeny 
CAP177 Non-homogenous 
CAP210 Follows a star-phylogeny 
CAP239 Follows a star-phylogeny 
CAP255 Non-homogenous 
Figure A1.1. Phylogenetic tree and highlighter plot of the C2C3 of CAP255 variants from the 
enrolment sample. A phylogenetic tree (left) and highlighter plot (right) of the C2C3 region were 
constructed using the twenty most common haplotypes of CAP255 sequences isolated from the enrolment 
sample (8 wpi). Two distinct variants were detected: three haplotypes represented the first variant (top three 
haplotypes) while one haplotype represented the second variant (fourth haplotype). The remainder of the 
haplotypes detected represented recombination of the two variants. 
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Figure A1.2. Phylogenetic tree and highlighter plot of the C2C3 of CAP177 variants from the 
enrolment and second samples. A phylogenetic tree (left) of the C2C3 region using the ten most common 
enrolment haplotypes (blue; 2 wpi) and ten most common haplotypes detected at the second sampling time 
(red; 4 wpi), and a highlighter plot (right) were constructed using CAP177 sequences isolated. One variant 
was detected at 2 wpi, but by 4 wpi a second variant (last four haplotypes) was detected.  
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Figure A1.3. DEAE-Dextran dependence of ten cell-free early/acute or mutant viruses. The DEAE-
dextran dependence of ten viruses (seven acute/early viruses and three mutant viruses) was determined by 
titrating the virus on TZM-bl cells in the presence and absence of DEAE-Dextran. Eight viruses were 
determined to be Dextran dependent, while two (CAP45 2.00 and CAP88 2.00) were Dextran independent. 
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Figure A1.4. Titration of PBMCs infected with eight early/acute or mutant viruses. PMBCs from eight 
viruses (five acute/early viruses and three mutant viruses) were titrated on TZM-bl cells in the presence and 
absence of DEAE-Dextran. All eight cell-associated viruses were Dextran independent. However, one virus 
(CAP177 TF) did not infect PBMCs at levels required for the cell-cell inhibition assay. 
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Figure A1.5. Determining the background signal from viruses secreted from infected PBMCs. 
Supernatant from infected PBMCs was collected at 12 hours, 24 hours and 48 hours and titrated on TZM-
bl cells to measure the background signal from cell-free viruses secreted from infected PBMCs. Secreted 
virus signal did not increase more than 10% over the cell control, indicating this did not account for 
significant levels of signal. 
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Appendix A2. List of infectious molecular clones 
IMC Identifier IMC name 
WPI env sequence 
was isolated 
Amino acid mutations from T/F 
Env 
Constructed by 
CAP8 TF pNL-LucR.T2A-C.CAP8.TF.ecto 3 - Ochsenbauer lab 
CAP45 TF pNL-LucR.T2A-C.CAP45.TF.ecto 5 - Ochsenbauer lab 
CAP45 TF D462G pNL-LucR.T2A-C.CAP45.TF.D462G.ecto - D462G Ochsenbauer lab 
CAP45 TF 460Δ3 pNL-LucR.T2A-C.CAP45.TF. 460Δ3.ecto - 460Δ3 Ochsenbauer lab
CAP61 2.00 pNL-LucR.T2A-C.CAP61.2.00.F10(J).ecto 8 - Ochsenbauer lab 
CAP88 2.00 pNL-LucR.T2A-C.CAP88.2.00.17_5A.ecto 5 - Ochsenbauer lab 
CAP177 TF pNL-LucR.T2A-C.CAP177.TF.ecto 4 - Ochsenbauer lab 
CAP210 TF pNL-LucR.T2A-C.CAP210.TF.ecto 2 - Ochsenbauer lab 
CAP210 TF A161V pNL-LucR.T2A-C.CAP210.TF.A161V.ecto - A161V Ochsenbauer lab 
CAP210 TF V208I pNL-LucR.T2A-C.CAP210.TF.V208I.ecto - V208I Ochsenbauer lab 
CAP228 2.00 pNL-LucR.T2A-C.CAP228.2.00.18.ecto 7 - Ochsenbauer lab 
CAP239 TF pNL-LucR.T2A-C.CAP239.TF.ecto 5 - D Mielke 
CAP239 TF K97E pNL-LucR.T2A-C.CAP239.TF.K97E.ecto - K97E D Mielke 
CAP239 TF L278S pNL-LucR.T2A-C.CAP239.TF.L278S.ecto - L278S D Mielke 
CAP239 TF S481N pNL-LucR.T2A-C.CAP239.TF.S481N.ecto - S481N D Mielke 
CAP239 13-5G3 pNL-LucR.T2A-C.CAP239.13-5G3.ecto 13 E462K, S481N, G600E D Mielke 
CAP239 13-9B2 pNL-LucR.T2A-C.CAP239.13-9B2.ecto 13 S481N D Mielke 
CAP239 13-9C6 pNL-LucR.T2A-C.CAP239.13-9C6.ecto 13 K171E, A221T, E340K, S481N D Mielke 
CAP239 19-7B2 pNL-LucR.T2A-C.CAP239.19-7B2.ecto 19 M95L, K117N, L278S, N397S, 
E462G, S481N 
D Mielke 
CAP239 19-7C2 pNL-LucR.T2A-C.CAP239.19-7C2.ecto 19 L278S, 462Δ3, S481N D Mielke 
CAP239 19-7E4 pNL-LucR.T2A-C.CAP239.19-7E4.ecto 19 K106E, D211N, W456R, K463.02E D Mielke 
CAP239 19-7F2 pNL-LucR.T2A-C.CAP239.19-7F2.ecto 19 K106E, V208I, W456R, K463.02E, 
I675N 
D Mielke 
CAP239 19-7F4 pNL-LucR.T2A-C.CAP239.19-7F4.ecto 19 A236T, S481N, S553N D Mielke 
CAP255 2.00 pNL-LucR.T2A-C.CAP255.2.00.5.ecto 8 - Ochsenbauer lab 
CAP256 2.00 pNL-LucR.T2A-C.CAP256.2.00.C7.ecto 6 - Ochsenbauer lab 
CAP257 2.00 pNL-LucR.T2A-C.CAP257.2.00.Lucifer.ecto 7 - Ochsenbauer lab 
Appendix A3. Obtaining an appropriate source of effector cells for the 
luciferase-based ADCC assay 
1. Introduction
A good source of effector cells is fundamental to a successful ADCC assay. Consequently, to 
establish the Luciferase-based ADCC assay at the University of Cape Town (UCT), an effective 
and constant source of appropriate effector cells was needed. The single nucleotide polymorphism 
(SNP) at position 158 of the FcγRIIIa has been identified as an important SNP for antibody Fc 
binding to FcγRIIIa (reviewed by Mellor et al. (323)), the major receptor involved in NK cell-
mediated ADCC. While a homogenous phenylalanine (158F/F) binds IgG1 strongly by allowing 
more flexibility of the FcγRIIIa receptor binding to the Fc region of antibodies, homogenous valine 
(158V/V) binds IgG1 weakly (324, 325). Currently, the Luciferase-based ADCC assay used in the 
Ferrari laboratory, from which this assay was learnt and established at UCT, uses 158F/V 
heterogenous PBMCs as the source of effector cells (Dr. Guido Ferrari, personal communication). 
2. Method
2.1. Ethics statement 
This sub-study received ethical approval from the University of Cape Town (914/2015). All 
participants in this study provided written informed consent for study participation.  
2.2. Study participants 
Fifteen participants were recruited for this study from within UCT with permission from the 
Department of Student Affairs and the Department of Human Resources, UCT. Participants were 
screened for HIV infection status, and 5 mL of blood was drawn to isolate PBMCs and screen 
PBMCs for genotype and functionality in the ADCC assay. 
One participant was chosen as a source of effector cells based on the above screening. 450 mL of 
blood was drawn once every 4 months, as per NIH guidelines. 
2.3.  Screening donors for FcγRIIIa 158F/V single nucleotide polymorphism 
Genomic DNA was extracted from donor PBMCs (1 x 106) using the Qiaprep DNA miniprep kit 
(Qiagen) as per manufacturer’s recommendations. PCR clean water was added to 5 ng of genomic 
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DNA and 1.25 μL of 20x Taqman genotyping probe mix (Assay ID C__25815666_10, SNP ID 
rs396991, Thermofisher Scientific) which contained VIC dye linked to the 5’ end of the Allele 1 
probe and 6FAM dye linked to the 5’ end of the Allele 2 probe, to a volume of 12.5 μL as per 
manufacturer’s recommendations. This was added to 12.5 μL of 2x Taqman Genotyping Master 
Mix (Thermofisher) to a total volume of 25 μL per reaction. A non-template control (NTC), as 
well as 158F/F, 158V/V and 158F/V template controls (kindly provided by Dr Ria Lassauniere, 
NICD, Johannesburg), were used as controls for allele detection. The PCR conditions were used 
as per manufacturer’s recommendations using a CFX96 Real-Time PCR Detection System 
(Biorad) and allelic discrimination analysis was carried out using CFX Manager Software (v3.1).  
2.4. Screening donor PBMCs for ADCC activity 
CEM.NKRCCR5 cells were infected with CAP239 TF as described in Chapter 3.2.9. The luciferase-
based ADCC assay was then performed as described in Chapter 3.2.11, using the A32 mAb and 
purified IgG from HIV-1 infected individuals (HIVIG) as sources of antibodies and PBMCs 
isolated from each donor as a source of effector cells.  
2.5.  Storage of PBMCs 
Isolated PBMCs were stored in liquid nitrogen at 20 x 106 cells/mL in RPMI supplemented with 
20% FCS (Biochrom) and 10% DMSO (Sigma). 
3. Results
3.1. Three donors had the 158F/V genotype 
Thirteen donors were recruited as potential donors of effector cells. 5 mL of blood was drawn from 
each participant and PBMCs were isolated from the blood. In 6 of the 13 participants, an 
insufficient number of PBMCs was isolated for genotype and ADCC analysis. Consequently, 
PBMCs from the remaining 7 participants were used for further analysis. Genomic DNA from 
these participants was extracted from the PBMCs and genotyped for the 158F/V polymorphism. 
Of the seven participants, three donors (donor 5, donor 7 and donor 13) had the 158F/V 
polymorphism (green) (Figure A3.1). 
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Figure A3.1. Scatter plot indicating the genotype of seven PBMC donors and four controls. The 
relative fluorescent units (RFU) for each probe binding to donor genomic DNA was determined. A NTC 
and controls for each of the genotypes (158FF, 158VV and 158FV) were used to determine the genotype 
of each participant. 
3.2.  Donor 7 had the highest ADCC activity using A32 and HIVIG against 
CAP239 TF-infected cells 
Having determined the genotype of the seven donors, we used PBMCs from each donor as a source 
of effector cells in ADCC assays, with the mAb A32 and HIVIG as a source of antibodies and 
CAP239 TF-infected cells as a source of target cells. Of the seven donors, donor 7 had the highest 
ADCC activity (Figure A3.2). As donor 7 had the correct genotype as well (158F/V), PBMCs from 
this donor were isolated and used in all subsequent ADCC assays. 
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Figure A3.2. ADCC activity against CAP239 TF using A32 and HIVIG and PBMCs from seven 
donors as a source of effector cells. The % specific killing of target cells using donor PBMCs as effector 
cells is shown over serial dilutions of A32 (red) and HIVIG (blue). 
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Appendix A4. List of primers used 































































Forward 5957-5982 CCACGGCTTAGGCATTTCCTATGGCAGGAAGAA 
EnvN Cloning 
primer 
Reverse 83-60 TTGCCAATCAAGGAAGTAGCCTTGTGT 








OFM19 Envelope nested 
PCR outer 
primers 
Forward 4903-4923 GCACTCAAGGCAAGCTTTATTGAGGCTTA 
VIF1 Reverse 544-519 GGGTTTATTACAGGGACAGCAGAG 
EnvA Envelope nested 
PCR inner 
primers 
Forward 5957-5982 GGCTTAGGCATTTCCTATGGCAGGAAGAA 
EnvN Reverse 83-60 TTGCCAATCAAGGAAGTAGCCTTGTGT 
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Table A4.4. HIV-1 subtype C envelope sequencing primers 
Primer name Hxb2 position Sequence (5’-3’) 
EF00 6201-6228 GGGAAAGAGCAGAAGACAGTGGCAATGA 
FOR14 6556-6582 TATGGGACCAAAGCCTAAAGCCATGTG 
FOR16 7350-7375 TTTAATTGTGGAGGAGAATTTTTCTA 
EF170 7799-7816 AGCAGGAAGCACTATGGG 
EF200 8092-8118 GGGATAACATGACCTGGATGCAGTGGG 
EF260 8520-8544 TTCAGCTACCACCGATTGAGAGACT 
EF175 6401-6378 TTTAGCATCTGATGCACAGAATAG 
REV15 7015-6990 CTGCCATTTAACAGCAGTTGAGTTGA 
EF115 7374-7397 AGAAAAATTCTCCTCTACAATTAA 
EF55 7940-7914 GCCCCAGACCGTGAGTTGCAACATATG 
EF15 8445-8466 TGCTCTCCACCTTCTTCTTC 
REV19 8820-8797 ACTTTTTGACCACTTGCCACCCAT 
Table A4.5. Mutagenesis primers 




















Appendix A5. List of monoclonal antibodies used 





VRC01 CD4-binding site 
Neutralizing 
(229, 306) 
3BNC117 CD4-binding site (306, 309) 
2G12 C2,C3,C4,V4 glycans (229, 236) 
PG9 V2 (326) 
697D V2 (231) 
PGT151 Gp120-gp41 interface (327) 
10E8 MPER (306) 




A32 CD4i cluster A (C1) (229) 
HG107 V2 (231) 
CH58 V2 (231)
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Appendix A6. Infection analysis 
Figure A6.1. Example of p24 staining analysis using mock- and CAP239 TF-infected cells. Mock (top) 
and CAP239 TF-infected cells (bottom) were stained with live/dead aqua (middle). Live cells were gated 
for and % p24 staining was measured in viable cells (right). 
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Table A6.1. Relative light units of target cells and p24 staining of viruses used in this study. 
Virus name Average RLUs of 5000 target cells Average % p24 cells 
CAP8 TF 541345 72.3 
CAP45 TF 44936 88.3 
CAP45 TF D462G 65457 35.4 
CAP45 TF 460Δ3* 8494 3.79 
CAP61 2.00 27949 15.9 
CAP88 2.00 116711 42.6 
CAP177 TF* 4732 2.19 
CAP210 TF 124261 38.2 
CAP210 TF A161V 43826 30.4 
CAP210 TF V208I 21613 12.4 
CAP228 2.00 1099962 26.4 
CAP239 TF 125016 93.2 
CAP239 TF K97E 171866 35.4 
CAP239 TF L278S 268758 39.3 
CAP239 TF S481N 85293 29.9 
CAP239 13-5G3 91438 22.8 
CAP239 13-9B2 134942 37.1 
CAP239 13-9C6 294575 44.2 
CAP239 19-7B2 797150 75.7 
CAP239 19-7C2 1520528 87.3 
CAP239 19-7E4 399972 56.6 
CAP239 19-7F2 447028 68.5 
CAP239 19-7F4 861928 79.2 
CAP255 2.00 78297 16.2 
CAP256 2.00* 9223 8.41 
CAP257 2.00 98344 15.3 
*Env-IMCs did not infect CEM.NKRCCR5 cells at levels high enough to use for ADCC assays.
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Appendix A7. Standard buffers and solutions 
A7.1. Luria Broth (LB) 
10 g Tryptone, 5 g yeast extract, 10 g NaCl 
Dissolved in 1 L distilled H2O and sterilized by autoclaving. 
A7.2. Luria Agar (LA) 
10 g Tryptone, 5 g yeast extract, 10 g NaCl,  15 g Bacto agar 
Dissolved in 1 L distilled H2O  and sterilized by autoclaving. 
A7.3. Tris-Acetate-EDTA (TAE, 50X) 
242 Tris base (Sigma) dissolved in 500 mL distilled H2O, 57.1 mL glacial acetic 
added, 100 mL 0.5 M EDTA (pH 8.0) solution 
Adjust volume to 1 L with distilled H2O and sterilize by autoclaving. 
A7.4. Carbenicillin 
1 g Carbenicillin powder (Sigma) in 10 mL distilled H2O. 
Filter sterilized using a 0.22 µL filter.  
Aliquoted into 500 µL aliquots and stored at room temperature. 
A7.5. 1% agarose gel 
100g SeaKem Agarose powder (Lonza) dissolved 1L 1x TAE 
A7.6. pcDNA™3.1/V5-His-TOPO®   
10 ng/μl plasmid DNA in: 50% glycerol, 50 mM Tris-HCl, pH 7.4 (at 25 °C),  
1 mM EDTA, 2 mM DTT, 0.1% TritonR X-100, 100 μg/mL BSA,  
30 μM phenol red 
A7.7. Growth media 
Complete growth media for adherent human tissue cell lines consisted of High 
glucose DMEM with L-glutamine and 25 mM HEPES (Lonza) supplemented with 
10 % FCS (Biochrom) and 100 μg/mL Gentamicin (Lonza). 
A7.8. R10 media 
R10 growth media for suspension human tissue cell likes consisted of RPMI 1640 
medium (Lonza) supplemented with 10% FCS (Biochrom) and 100 μg/mL 
Gentamicin (Lonza). 
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Appendix A8. Standard molecular biology techniques 
A8.1. Plasmid Transformation 
Top10 chemically competent cells were incubated on ice with 50 ng plasmid for 30 min to allow 
for equal distribution of DNA. The cells were heat shocked in a water bath for 30 s at 42 ºC to 
increase membrane permeability, and then incubated on ice for 2 min. 250 µL Luria Broth (LB) 
(Appendix A4) was added to the cells, which were then incubated for 60 min at 32 ºC to allow for 
expression of the ampicillin resistance gene of the vector. Subsequently, the cells were centrifuged 
at 7000 rpm for 3 min in a microcentrifuge, 150 µL media was removed and the cells were 
resuspended in the remaining 100 µL media. The resuspended cells were plated on Luria Agar 
(LA) (Appendix A7.2) containing 100 mg/mL Carbenicillin (an ampicillin analogue) (Sigma) 
(Appendix A7.4) and incubated at 37 ºC overnight. 
A8.2. Viral RNA extraction 
200 µL plasma was added to 800 µL prepared buffer AVL containing carrier RNA and mixed by 
pulse-vortexing for 15 s. The resulting solution was incubated at room temperature for 10 minutes 
to allow for complete viral particle lysis. 800 µL of 100% ethanol was added and mixed to the 
sample by pulse-vortexing for 15 s.   
630 µL of the solution was applied to a QIAamp Mini column (Qiagen) and centrifuged at 8000 
rpm for 1 min in a microcentrifuge. The column was placed in a clean 2 mL collection tube and 
the process was repeated until all the solution was applied to the column.  
500 µL buffer AW1 was applied to the and the column was centrifuged at 8000 rpm for 1 min in 
a microcentrifuge. The filtrate was discarded and 500 µL buffer AW2 was applied to the column. 
The column was then centrifuged at 14000 rpm for 3 min in a microcentrifuge. The column was 
then placed in a clean 1.5 mL microcentrifuge tube. 50 µL buffer AVE was added to the column 
and allowed to incubate at room temperature for 1 min. The column was then centrifuged at 8000 
rpm for 1 min in a microcentrifuge. The filtrate was collected and stored at -20 ºC till further 
required. 
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A8.3. Agarose gel electrophoresis 
DNA fragments were visualised in 1-2% agarose gels. Agarose gel electrophoresis was performed 
using horizontal gel apparatus (Stratagene). The agarose gel was prepared by melting the 
appropriate weight per volume agarose (SeaKem Agarose, Lonza) poured into gel setting trays 
and allowed to cool to room temperature to set. Set gels were placed in a gel apparatus submerged 
in 1x TAE. Before loading, 3-5 μL PCR product mixed with 1 μL of 6x agarose gel electrophoresis 
loading dye. To determine the size of amplicons a DNA molecular weight marker, 1 kB plus 
O’GeneRuler (Thermofisher Scientific) was included in the first and last lanes of all gels. The gel 
was electrophoresed at 100 to 120 V according to gel size for 60 minutes or until sufficient 
separation of bands. The DNA fragments were visualized on a UVP transilluminator (UVP) at 256 
nm wavelength and photographed with Kodak ds 1D Electrophoresis Documentation and Analysis 
System 120 V2.0.3 computerized gel imager. 
A8.4. Gel Extraction 
The gel was visualized under UV using a UviPro gel visualizer (Uvitec). DNA of the expected size 
was excised from the gel quickly using scalpel and transferred into a previously weighed 1.5 mL 
microcentrifuge tube. The gel and microcentrifuge tube were then weighed again to determine the 
mass of the gel excised. A Zymoclean Gel DNA Recovery Kit (Zymo Research) was then used as 
instructed by manufacturers. Briefly, 3 volumes of Agarose Dissolving Buffer (ADB) was added 
foe each volume of agarose excised from the gel (e.g. 300 µL of ADB for every 100 mg of agarose 
gel) and incubated at 50 °C for 15 min until the agarose had completely dissolved. The melted 
agarose solution was then transferred to a Zymo-Spin column in a collection tube and centrifuged 
for 60 s at 13200 rpm in a microcentrifuge. 200 µL DNA wash buffer was added to the column 
and centrifuged for 30 s at 13200 rpm in a microcentrifuge. This step was repeated. 10 µL PCR-
grade water (Sigma) was added directly to the column matrix and this was centrifuged for 60 s at 
13200 rpm in a microcentrifuge. The concentration, A260/A280 and A260/A230 of the excised DNA 
was then measured using a NanoDrop spectrophotometer (ThermoScientific). 
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